genesymbol,entrezgene,variant_name,variant_description,variant_groups,api_url,api_variant_id,chromosome,chr_start,chr_stop,refbase,altbase,refbuild,evidence_type,evidence_level,evidence_description,evidence_direction,clinical_significance,variant_origin,status,type,pubmed_id,pubmed_html_link,disease_name,disease_ontology_id,disease_url,drug_names,drug_interaction_type,rating
CDKN2A,1029,LOSS,NA,NA,https://civic.genome.wustl.edu/api/variants/554,554,9,21967752,21994623,NA,NA,GRCh37,Predictive,D: Preclinical evidence,"A patient-derived xenograft (PDX) from a patient with cyclin-dependent kinase inhibitor 2A/B (CDKN2A/B) loss and FUS-ERG fusion positive Ewing's sarcoma was created. The PDX was treated in four cohorts (each N=6) with control, doxorubicin, CDK4/6 inhibitor palbociclib or IGF-1R inhibitor linsitinib. Both linsitinib and palbociclib cohorts were significantly more effective than control and doxorubicin. Doxorubicin was part of the patient's treatment (Neoadjuvant chemotherapy with DOX, vincristine, and cyclophosphamide) and was noted by authors as failing to control tumor growth.",Supports,Sensitivity,Somatic Mutation,accepted,evidence,27286459,"<a href='http://www.ncbi.nlm.nih.gov/pubmed/27286459' target='_blank'>Murakami et al., 2016, Oncotarget</a>",Ewing Sarcoma,3369,http://www.disease-ontology.org/?id=DOID:3369,"Linsitinib, Palbociclib",Substitutes,2
CDKN2A,1029,LOSS,NA,NA,https://civic.genome.wustl.edu/api/variants/554,554,9,21967752,21994623,NA,NA,GRCh37,Predictive,D: Preclinical evidence,"Preclinical study of the effects of PD-0332991 on proliferation, cell-cycle, apoptosis, and Rb phosphorylation in a panel of 40 human ovarian cancer cell lines. Concentration-dependent antiproliferative effects of PD-0332991 were seen in all ovarian cancer cell lines, but varied significantly between individual lines. Rb-proficient cell lines with low p16 expression were significantly more sensitive to PD-0332991 (as defined by IC50 < mean) in mRNA expression (Agilent), protein level (Western Blot) and copy number (Array CGH) analyses.",Supports,Sensitivity,Somatic Mutation,accepted,evidence,21278246,"<a href='http://www.ncbi.nlm.nih.gov/pubmed/21278246' target='_blank'>Konecny et al., 2011, Clin. Cancer Res.</a>",Ovarian Cancer,2394,http://www.disease-ontology.org/?id=DOID:2394,Palbociclib (PD0332991),NA,3
CDKN2A,1029,LOSS,NA,NA,https://civic.genome.wustl.edu/api/variants/554,554,9,21967752,21994623,NA,NA,GRCh37,Predictive,D: Preclinical evidence,"In a cohort of 143 patients with primary invasive melanoma hemizygous or homozygous loss of CDKN2A was observed (FISH) in 56% of cases. PD0332991 efficacy (proliferation assay) was assessed in a panel of 47 melanoma cell lines. Loss of functional p16INK4A (CDKN2A) due to gene deletion (49% of cells), methylation (4% of cells), or mutation (19% of cells) was the most prevalent alteration occurring in 71% of cell lines, and significantly correlated with PD0332991 sensitivity (Fisher's exact test P < 0.02).",Supports,Sensitivity,Somatic Mutation,accepted,evidence,24495407,"<a href='http://www.ncbi.nlm.nih.gov/pubmed/24495407' target='_blank'>Young et al., 2014, Pigment Cell Melanoma Res</a>",Skin Melanoma,8923,http://www.disease-ontology.org/?id=DOID:8923,Palbociclib (PD0332991),NA,3
CDKN2A,1029,LOSS,NA,NA,https://civic.genome.wustl.edu/api/variants/554,554,9,21967752,21994623,NA,NA,GRCh37,Predictive,D: Preclinical evidence,"Preclinical study of CDK4/6 inhibitor PD-0332991 in 28 renal carcinoma cell lines (25 malignant RCC and three non-malignant, transformed cell lines derived from kidney epithelium). Both p15 and p16 loss (CGH) were tested for association with response to PD-0332991 using Fisher's exact test. Cell lines with p16 and p15 losses were significantly more likely to be classified as responders (defined by pharmacokinetic data-based concentration of <=400nM) to PD-0332991 (p=0.027, relative risk (RR)=2.06 and p=0.047, RR=1.71, respectively). Four cell lines had homozygous deletions of CDKN2A but not CDKN2B, and three of these lines were classified as being sensitive to PD-0332991. There were no cell lines with only CDKN2B deletion.",Supports,Sensitivity,Somatic Mutation,accepted,evidence,23898052,"<a href='http://www.ncbi.nlm.nih.gov/pubmed/23898052' target='_blank'>Logan et al., 2013, Anticancer Res.</a>",Renal Cell Carcinoma,4450,http://www.disease-ontology.org/?id=DOID:4450,Palbociclib (PD0332991),NA,3
CDKN2A,1029,LOSS,NA,NA,https://civic.genome.wustl.edu/api/variants/554,554,9,21967752,21994623,NA,NA,GRCh37,Predictive,D: Preclinical evidence,"Preclinical study in 9 melanoma cell lines. Three cell lines did not have CDKN2A (p16) mutations and showed expression of the protein on western blot analysis. Two of the other six cell lines had stop codons leading to a truncated protein, and three had missense mutations with evidence of protein expression on western blot (two cell lines with a P114L mutation and one with an E88K mutation). Mean IC50s of flavopiridol were significantly lower in cell lines with a mutated or non-expressed p16 (p16-) (mean 50% inhibitory concentration [IC(50)] = 12.5 nM), than in cell lines with intact p16 (p16+) (mean IC(50) = 25 nM).",Supports,Sensitivity,Somatic Mutation,accepted,evidence,12777976,"<a href='http://www.ncbi.nlm.nih.gov/pubmed/12777976' target='_blank'>Robinson et al., 2003, Melanoma Res.</a>",Skin Melanoma,8923,http://www.disease-ontology.org/?id=DOID:8923,Flavopiridol,NA,2
CDKN2A,1029,LOSS,NA,NA,https://civic.genome.wustl.edu/api/variants/554,554,9,21967752,21994623,NA,NA,GRCh37,Predictive,C: Case study,"A patient with metastatic ER-positive, her2-negative breast cancer with CDKN2A loss experienced a short-lived (~3-month) clinical response to palbociclib when given in combination with letrozole.",Supports,Sensitivity,Somatic Mutation,accepted,evidence,26715889,"<a href='http://www.ncbi.nlm.nih.gov/pubmed/26715889' target='_blank'>Gao et al., 2015, Curr Oncol</a>",Her2-receptor Negative Breast Cancer,60080,http://www.disease-ontology.org/?id=DOID:0060080,"Letrozole, Palbociclib (PD0332991)",Combination,3
CDKN2A,1029,LOSS,NA,NA,https://civic.genome.wustl.edu/api/variants/554,554,9,21967752,21994623,NA,NA,GRCh37,Predictive,D: Preclinical evidence,"An imatinib-resistant cell line, DFSP105, was established from a dermatofibrosarcoma protuberans which had progressed to a high-grade fibrosarcomatous DFSP. The disease-associated PDGFB-COL1A1 fusion was consistent with the most common form, a supernumerary ring chromosome. Genetic characterization of the cell line with a SNP array identified a homozygous CDKN2A/B deletion. Treatment of this cell line with CDK4/6 inhibitor palbociclib led to growth inhibition and reduced RB1 phosphorylation in vitro and in-vivo.",Supports,Sensitivity,Unknown,accepted,evidence,25852058,"<a href='http://www.ncbi.nlm.nih.gov/pubmed/25852058' target='_blank'>Eilers et al., 2015, Mol. Cancer Ther.</a>",Dermatofibrosarcoma Protuberans,3507,http://www.disease-ontology.org/?id=DOID:3507,Palbociclib,NA,2
CDKN2A,1029,LOSS,NA,NA,https://civic.genome.wustl.edu/api/variants/554,554,9,21967752,21994623,NA,NA,GRCh37,Predictive,D: Preclinical evidence,"Short term explant cultures from 20 glioblastoma multiforme (GBM) tumor xenograft lines were evaluated for CDKN2A (p16 aka INK4A) expression by western blot and RT-PCR as well as deletion by aCGH and Sanger sequencing. Two lines with intact CDKN2A showed resistance to the CDK4/6 inhibitor palbociclib (PD0332991). The two resistant lines had additional mutations (RB1 mutation or CDK4 amplification).  In contrast, three CDKN2A mutant (homozygous deletion) lines showed significant growth inhibition in comparison to vehicle/DMSO controls.  Screening of another 20 lines identified one with CDKN2A deletion and wildtype CDK4 which was tested in vitro and in vivo, and found to be sensitive to palbociclib.",Supports,Sensitivity,Somatic Mutation,submitted,evidence,22711607,"<a href='http://www.ncbi.nlm.nih.gov/pubmed/22711607' target='_blank'>Cen et al., 2012, Neuro-oncology</a>",Glioblastoma Multiforme,3068,http://www.disease-ontology.org/?id=DOID:3068,Palbociclib (PD0332991),NA,2
EGFR,1956,Ex19 del L858R,NA,NA,https://civic.genome.wustl.edu/api/variants/1854,1854,,NA,NA,NA,NA,NA,Predictive,B: Clinical evidence,"The phase 3 (EURTAC) study consisted of of 173 non-small cell lung cancer patients who had not had prior chemotherapy for metastatic disease (although adjuvant or neoadjuvant chemotherapy was permitted) and included 160 patients with lung adenocarcinoma subtype. The patients had EGFR mutations (exon 19 deletions or L858R), and improved progression-free survival was reported in the erlotinib treated cohort as compared to the cohort that was treated with standard chemotherapy (9.7mo vs. 5.2mo, HR:0.37, 95%CI:0.25-0.54, P<0.0001, univariate analysis; HR:0.35, 95%CI:0.23-0.52, P<0.0001, multivariate analysis).",Supports,Sensitivity,Somatic Mutation,accepted,evidence,22285168,"<a href='http://www.ncbi.nlm.nih.gov/pubmed/22285168' target='_blank'>Rosell et al., 2012, Lancet Oncol.</a>",Lung Adenocarcinoma,3910,http://www.disease-ontology.org/?id=DOID:3910,Erlotinib,NA,4
EGFR,1956,Ex19 del L858R,NA,NA,https://civic.genome.wustl.edu/api/variants/1854,1854,,NA,NA,NA,NA,NA,Predictive,B: Clinical evidence,"In a study of 1261 non-small cell lung cancer patients, 49.8% of the analyzed tumors had EGFR mutations including deletions in exon 19 (n=258), L858R (n=260), T790M (n=6) and insertions or duplications in exon 20 (n=25). Patients with EGFR deletions in exon 19 or L858R mutations were associated with an improved response to erlotinib or gefitinib with partial or complete response (74.1% vs. 16.5%, P<0.001) when compared to wildtype EGFR patients. Additionally, tumors with EGFR mutations in L858R or deletions in exon 19 were associated with increased overall survival (19.6mo vs. 10.4mo) compared to wildtype (all patients were treated with either erlotinib or gefitinib). From 61 patients with uncommon EGFR mutations of unknown clinical significance, 47.5% were responders in contrast to the 74.1% responders in the exon 19 deletion/L858R group.",Supports,Sensitivity,Somatic Mutation,accepted,evidence,21531810,"<a href='http://www.ncbi.nlm.nih.gov/pubmed/21531810' target='_blank'>Wu et al., 2011, Clin. Cancer Res.</a>",Non-small Cell Lung Carcinoma,3908,http://www.disease-ontology.org/?id=DOID:3908,"Gefitinib, Erlotinib",Substitutes,4
EGFR,1956,Ex19 del L858R,NA,NA,https://civic.genome.wustl.edu/api/variants/1854,1854,,NA,NA,NA,NA,NA,Predictive,C: Case study,"A phase 2 study of 120 stage IIIB-IV lung adenocarcinoma patients reported improved progression free survival in patients with EGFR mutation (defined as exon 19 deletion or exon 21 mutation) when treated (n=13) with gefitinib and pemetrexed/platinum combination therapy (HR: 0.20, 95% CI: 0.05-0.75, P=0.017) as compared to treatment (n=18) with pemtrexed/platinum alone.  In the subgroup of patients without EGFR mutation (defined as all patients without the specific EGFR exon 19 deletion or L858R mutation) a difference in median PFS was not seen between the chemotherapy versus chemotherapy with gefitinib treatment groups.",Supports,Sensitivity,Somatic Mutation,accepted,evidence,24755888,"<a href='http://www.ncbi.nlm.nih.gov/pubmed/24755888' target='_blank'>Yu et al., 2014, Cancer Biol. Ther.</a>",Non-small Cell Lung Carcinoma,3908,http://www.disease-ontology.org/?id=DOID:3908,Gefitinib,NA,4
EGFR,1956,T790M,"EGFR T790M was one of the very first mutations recognized to confer resistance to targeted therapies in non-small cell lung cancer. While successful in amplified EGFR, the efficacy of the first and second generation TKI's (erlotinib, gefitinib, neratinib) in treating patients harboring this mutation before treatment is notably lower. This lack of efficacy can likely be to blame for the poorer prognosis for patients with this mutation as compared to patients with wildtype EGFR or other types of EGFR mutations. Approximately half of EGFR mutant tumors with acquired resistance to TKI inhibition have been shown to harbor this mutation, implicating it as a mechanism of acquired therapy resistence. A third generation TKI (osimertinib) has been approved for the treatment of EGFR T790M mutant NSCLC. Patients positive for T790M in a plasma-based test have similar outcomes like those with tumor biopsy testing.",EGFR TKI Resistance,https://civic.genome.wustl.edu/api/variants/34,34,7,55249071,55249071,C,T,GRCh37,Predictive,D: Preclinical evidence,"Lung cancers can accumulate activating mutations in oncogenes such as EGFR. The common L858R EGFR mutation has been shown previously to be sensitive to small molecular tyrosine kinase inhibitors (ie. erlotinib). In response, tumors may accumulate an additional 'gatekeeper' mutation in EGFR, T790M. Authors show that T790M retain low affinity for gefitinib and that introduction of T790M in the presence of L858R mutant increases the ATP affinity of L858R and activates wild-type EGFR, thus showing that increased ATP affinity is the primary mode of resistance in tumors with T790M, though irreversible ATP inhibitors (ie. HKI-272) are able to overcome this resistance via covalent bonding.",Supports,Resistance or Non-Response,Somatic Mutation,accepted,evidence,18227510,"<a href='http://www.ncbi.nlm.nih.gov/pubmed/18227510' target='_blank'>Yun et al., 2008, Proc. Natl. Acad. Sci. U.S.A.</a>",Lung Cancer,1324,http://www.disease-ontology.org/?id=DOID:1324,"Gefitinib, AEE788",Sequential,5
EGFR,1956,T790M,"EGFR T790M was one of the very first mutations recognized to confer resistance to targeted therapies in non-small cell lung cancer. While successful in amplified EGFR, the efficacy of the first and second generation TKI's (erlotinib, gefitinib, neratinib) in treating patients harboring this mutation before treatment is notably lower. This lack of efficacy can likely be to blame for the poorer prognosis for patients with this mutation as compared to patients with wildtype EGFR or other types of EGFR mutations. Approximately half of EGFR mutant tumors with acquired resistance to TKI inhibition have been shown to harbor this mutation, implicating it as a mechanism of acquired therapy resistence. A third generation TKI (osimertinib) has been approved for the treatment of EGFR T790M mutant NSCLC. Patients positive for T790M in a plasma-based test have similar outcomes like those with tumor biopsy testing.",EGFR TKI Resistance,https://civic.genome.wustl.edu/api/variants/34,34,7,55249071,55249071,C,T,GRCh37,Predictive,B: Clinical evidence,"In a phase1-2 study, patients with the T790M mutation were more sensitive to rocelitinib in comparison to patients with T790M-negative NSCLC.",Supports,Sensitivity,Somatic Mutation,accepted,evidence,25923550,"<a href='http://www.ncbi.nlm.nih.gov/pubmed/25923550' target='_blank'>Sequist et al., 2015, N. Engl. J. Med.</a>",Non-small Cell Lung Carcinoma,3908,http://www.disease-ontology.org/?id=DOID:3908,Rociletinib,NA,4
EGFR,1956,T790M,"EGFR T790M was one of the very first mutations recognized to confer resistance to targeted therapies in non-small cell lung cancer. While successful in amplified EGFR, the efficacy of the first and second generation TKI's (erlotinib, gefitinib, neratinib) in treating patients harboring this mutation before treatment is notably lower. This lack of efficacy can likely be to blame for the poorer prognosis for patients with this mutation as compared to patients with wildtype EGFR or other types of EGFR mutations. Approximately half of EGFR mutant tumors with acquired resistance to TKI inhibition have been shown to harbor this mutation, implicating it as a mechanism of acquired therapy resistence. A third generation TKI (osimertinib) has been approved for the treatment of EGFR T790M mutant NSCLC. Patients positive for T790M in a plasma-based test have similar outcomes like those with tumor biopsy testing.",EGFR TKI Resistance,https://civic.genome.wustl.edu/api/variants/34,34,7,55249071,55249071,C,T,GRCh37,Predictive,A: Validated,"The T790M mutation in EGFR has been shown to confer resistance to the tyrosine kinase inhibitor erlotinib, and patients harboring this mutation that are placed on the drug are likely to relapse.",Supports,Resistance or Non-Response,Somatic Mutation,accepted,evidence,25668228,"<a href='http://www.ncbi.nlm.nih.gov/pubmed/25668228' target='_blank'>Denis et al., 2015, Clin. Chim. Acta</a>",Non-small Cell Lung Carcinoma,3908,http://www.disease-ontology.org/?id=DOID:3908,Erlotinib,NA,5
EGFR,1956,T790M,"EGFR T790M was one of the very first mutations recognized to confer resistance to targeted therapies in non-small cell lung cancer. While successful in amplified EGFR, the efficacy of the first and second generation TKI's (erlotinib, gefitinib, neratinib) in treating patients harboring this mutation before treatment is notably lower. This lack of efficacy can likely be to blame for the poorer prognosis for patients with this mutation as compared to patients with wildtype EGFR or other types of EGFR mutations. Approximately half of EGFR mutant tumors with acquired resistance to TKI inhibition have been shown to harbor this mutation, implicating it as a mechanism of acquired therapy resistence. A third generation TKI (osimertinib) has been approved for the treatment of EGFR T790M mutant NSCLC. Patients positive for T790M in a plasma-based test have similar outcomes like those with tumor biopsy testing.",EGFR TKI Resistance,https://civic.genome.wustl.edu/api/variants/34,34,7,55249071,55249071,C,T,GRCh37,Predictive,B: Clinical evidence,"In non-small cell lung cancer, the appearance of T790M mutation leads to resistance to gefitinib.",Supports,Resistance or Non-Response,Somatic Mutation,accepted,evidence,15728811,"<a href='http://www.ncbi.nlm.nih.gov/pubmed/15728811' target='_blank'>Kobayashi et al., 2005, N. Engl. J. Med.</a>",Non-small Cell Lung Carcinoma,3908,http://www.disease-ontology.org/?id=DOID:3908,Gefitinib,NA,3
EGFR,1956,T790M,"EGFR T790M was one of the very first mutations recognized to confer resistance to targeted therapies in non-small cell lung cancer. While successful in amplified EGFR, the efficacy of the first and second generation TKI's (erlotinib, gefitinib, neratinib) in treating patients harboring this mutation before treatment is notably lower. This lack of efficacy can likely be to blame for the poorer prognosis for patients with this mutation as compared to patients with wildtype EGFR or other types of EGFR mutations. Approximately half of EGFR mutant tumors with acquired resistance to TKI inhibition have been shown to harbor this mutation, implicating it as a mechanism of acquired therapy resistence. A third generation TKI (osimertinib) has been approved for the treatment of EGFR T790M mutant NSCLC. Patients positive for T790M in a plasma-based test have similar outcomes like those with tumor biopsy testing.",EGFR TKI Resistance,https://civic.genome.wustl.edu/api/variants/34,34,7,55249071,55249071,C,T,GRCh37,Predictive,B: Clinical evidence,"In Lung Cancer patients with acquired resistance to Dacomitinib (PF00299804), MET amplification and EGFR T790M were found to be the primary drivers of resistance.",Supports,Resistance or Non-Response,Somatic Mutation,accepted,evidence,21430269,"<a href='http://www.ncbi.nlm.nih.gov/pubmed/21430269' target='_blank'>Sequist et al., 2011, Sci Transl Med</a>",Non-small Cell Lung Carcinoma,3908,http://www.disease-ontology.org/?id=DOID:3908,Dacomitinib,NA,4
EGFR,1956,T790M,"EGFR T790M was one of the very first mutations recognized to confer resistance to targeted therapies in non-small cell lung cancer. While successful in amplified EGFR, the efficacy of the first and second generation TKI's (erlotinib, gefitinib, neratinib) in treating patients harboring this mutation before treatment is notably lower. This lack of efficacy can likely be to blame for the poorer prognosis for patients with this mutation as compared to patients with wildtype EGFR or other types of EGFR mutations. Approximately half of EGFR mutant tumors with acquired resistance to TKI inhibition have been shown to harbor this mutation, implicating it as a mechanism of acquired therapy resistence. A third generation TKI (osimertinib) has been approved for the treatment of EGFR T790M mutant NSCLC. Patients positive for T790M in a plasma-based test have similar outcomes like those with tumor biopsy testing.",EGFR TKI Resistance,https://civic.genome.wustl.edu/api/variants/34,34,7,55249071,55249071,C,T,GRCh37,Predictive,C: Case study,"In an NSCLC patient initially with L858R mutation, pemetrexed and cisplatin combination treatment was followed by erlotinib treatment. A slow progression developed which was found to be positive for L858R as well as T790M mutation which confers resistance to tyrosine kinase inhibitors. Due to slow tumor growth erlotinib was continued despite T790M, with re-addition of premetrexed, and this reduced tumor size and resulted in stable disease.",Supports,Sensitivity,Somatic Mutation,accepted,evidence,24636847,"<a href='http://www.ncbi.nlm.nih.gov/pubmed/24636847' target='_blank'>Li et al., 2014, Lung Cancer</a>",Non-small Cell Lung Carcinoma,3908,http://www.disease-ontology.org/?id=DOID:3908,"Erlotinib, Pemetrexed",Combination,3
EGFR,1956,T790M,"EGFR T790M was one of the very first mutations recognized to confer resistance to targeted therapies in non-small cell lung cancer. While successful in amplified EGFR, the efficacy of the first and second generation TKI's (erlotinib, gefitinib, neratinib) in treating patients harboring this mutation before treatment is notably lower. This lack of efficacy can likely be to blame for the poorer prognosis for patients with this mutation as compared to patients with wildtype EGFR or other types of EGFR mutations. Approximately half of EGFR mutant tumors with acquired resistance to TKI inhibition have been shown to harbor this mutation, implicating it as a mechanism of acquired therapy resistence. A third generation TKI (osimertinib) has been approved for the treatment of EGFR T790M mutant NSCLC. Patients positive for T790M in a plasma-based test have similar outcomes like those with tumor biopsy testing.",EGFR TKI Resistance,https://civic.genome.wustl.edu/api/variants/34,34,7,55249071,55249071,C,T,GRCh37,Predictive,E: Indirect evidence,"In NSCLC containing a T790M mutation, staurosporine may be inhibitive of EGFR, especially when an L858R mutation is also present.",Supports,Sensitivity,Somatic Mutation,accepted,evidence,24658966,"<a href='http://www.ncbi.nlm.nih.gov/pubmed/24658966' target='_blank'>Ai et al., 2014, Amino Acids</a>",Non-small Cell Lung Carcinoma,3908,http://www.disease-ontology.org/?id=DOID:3908,Staurosporine,NA,1
EGFR,1956,T790M,"EGFR T790M was one of the very first mutations recognized to confer resistance to targeted therapies in non-small cell lung cancer. While successful in amplified EGFR, the efficacy of the first and second generation TKI's (erlotinib, gefitinib, neratinib) in treating patients harboring this mutation before treatment is notably lower. This lack of efficacy can likely be to blame for the poorer prognosis for patients with this mutation as compared to patients with wildtype EGFR or other types of EGFR mutations. Approximately half of EGFR mutant tumors with acquired resistance to TKI inhibition have been shown to harbor this mutation, implicating it as a mechanism of acquired therapy resistence. A third generation TKI (osimertinib) has been approved for the treatment of EGFR T790M mutant NSCLC. Patients positive for T790M in a plasma-based test have similar outcomes like those with tumor biopsy testing.",EGFR TKI Resistance,https://civic.genome.wustl.edu/api/variants/34,34,7,55249071,55249071,C,T,GRCh37,Predictive,D: Preclinical evidence,"In an in vitro study, a Ba/F3 cell line expressing EGFR S752_I759del demonstrated increased sensitivity to erlotinib treatment (IC50=33nM), comparable to Ba/F3 cells expressing EGFR L858R (a known sensitizing mutation to EGFR tyrosine kinase inhibitors; IC50=16nM). Sensitivity was determined by assessing IL-3 independent cell survival.",Supports,Sensitivity,Somatic Mutation,submitted,evidence,17877814,"<a href='http://www.ncbi.nlm.nih.gov/pubmed/17877814' target='_blank'>de Gunst et al., 2007, Mol. Cancer</a>",Non-small Cell Lung Carcinoma,3908,http://www.disease-ontology.org/?id=DOID:3908,Erlotinib,NA,NA
EGFR,1956,T790M,"EGFR T790M was one of the very first mutations recognized to confer resistance to targeted therapies in non-small cell lung cancer. While successful in amplified EGFR, the efficacy of the first and second generation TKI's (erlotinib, gefitinib, neratinib) in treating patients harboring this mutation before treatment is notably lower. This lack of efficacy can likely be to blame for the poorer prognosis for patients with this mutation as compared to patients with wildtype EGFR or other types of EGFR mutations. Approximately half of EGFR mutant tumors with acquired resistance to TKI inhibition have been shown to harbor this mutation, implicating it as a mechanism of acquired therapy resistence. A third generation TKI (osimertinib) has been approved for the treatment of EGFR T790M mutant NSCLC. Patients positive for T790M in a plasma-based test have similar outcomes like those with tumor biopsy testing.",EGFR TKI Resistance,https://civic.genome.wustl.edu/api/variants/34,34,7,55249071,55249071,C,T,GRCh37,Predictive,C: Case study,"In a lung adenocarcinoma patient with EGFR E746_A751>A (a known erlotinib sensitizing mutation) and EGFR T790M co-mutation treated with erlotinib monotherapy, EGFR T790M was associated with disease progression. The patient was treated with erlotinib monotherapy and achieved a 10 month response rate, but subsequently developed disease progression upon emergence of the EGFR T790M mutation.",Supports,Resistance or Non-Response,Somatic Mutation,submitted,evidence,17085664,"<a href='http://www.ncbi.nlm.nih.gov/pubmed/17085664' target='_blank'>Balak et al., 2006, Clin. Cancer Res.</a>",Lung Adenocarcinoma,3910,http://www.disease-ontology.org/?id=DOID:3910,Erlotinib,NA,NA
EGFR,1956,T790M,"EGFR T790M was one of the very first mutations recognized to confer resistance to targeted therapies in non-small cell lung cancer. While successful in amplified EGFR, the efficacy of the first and second generation TKI's (erlotinib, gefitinib, neratinib) in treating patients harboring this mutation before treatment is notably lower. This lack of efficacy can likely be to blame for the poorer prognosis for patients with this mutation as compared to patients with wildtype EGFR or other types of EGFR mutations. Approximately half of EGFR mutant tumors with acquired resistance to TKI inhibition have been shown to harbor this mutation, implicating it as a mechanism of acquired therapy resistence. A third generation TKI (osimertinib) has been approved for the treatment of EGFR T790M mutant NSCLC. Patients positive for T790M in a plasma-based test have similar outcomes like those with tumor biopsy testing.",EGFR TKI Resistance,https://civic.genome.wustl.edu/api/variants/34,34,7,55249071,55249071,C,T,GRCh37,Predictive,C: Case study,"In a study of 6 patients with progressive non-small cell lung cancer during gefitinib or erlotinib therapy,  comparison of DNA sequences from the original diagnostic biopsy specimen and the second biopsy specimen demonstrated that 2 patients acquired a new EGFR-T790M mutation.",Supports,Resistance or Non-Response,Somatic Mutation,submitted,evidence,15737014,"<a href='http://www.ncbi.nlm.nih.gov/pubmed/15737014' target='_blank'>Pao et al., 2005, PLoS Med.</a>",Non-small Cell Lung Carcinoma,3908,http://www.disease-ontology.org/?id=DOID:3908,Erlotinib,NA,NA
EGFR,1956,T790M,"EGFR T790M was one of the very first mutations recognized to confer resistance to targeted therapies in non-small cell lung cancer. While successful in amplified EGFR, the efficacy of the first and second generation TKI's (erlotinib, gefitinib, neratinib) in treating patients harboring this mutation before treatment is notably lower. This lack of efficacy can likely be to blame for the poorer prognosis for patients with this mutation as compared to patients with wildtype EGFR or other types of EGFR mutations. Approximately half of EGFR mutant tumors with acquired resistance to TKI inhibition have been shown to harbor this mutation, implicating it as a mechanism of acquired therapy resistence. A third generation TKI (osimertinib) has been approved for the treatment of EGFR T790M mutant NSCLC. Patients positive for T790M in a plasma-based test have similar outcomes like those with tumor biopsy testing.",EGFR TKI Resistance,https://civic.genome.wustl.edu/api/variants/34,34,7,55249071,55249071,C,T,GRCh37,Predictive,D: Preclinical evidence,"In an in vitro study, a NCI-H1975 cell line expressing EGFR L858R and EGFR T790M co-mutation, EGFR T790M was associated with reduced sensitivity to erlotinib treatment compared to QG56 cells expressing EGFR wild-type. Sensitivity was determined by assessing cell viability (mean IC50 of erlotinib for cells expressing EGFR L858R and EGFR T790M co-mutations was 4.3 锟組 vs. 8.9 锟組 for EGFR wild-type expressing cells).",Supports,Resistance or Non-Response,Somatic Mutation,submitted,evidence,25853010,"<a href='http://www.ncbi.nlm.nih.gov/pubmed/25853010' target='_blank'>Abourbeh et al., 2015, EJNMMI Res</a>",Non-small Cell Lung Carcinoma,3908,http://www.disease-ontology.org/?id=DOID:3908,Erlotinib,NA,NA
EGFR,1956,T790M,"EGFR T790M was one of the very first mutations recognized to confer resistance to targeted therapies in non-small cell lung cancer. While successful in amplified EGFR, the efficacy of the first and second generation TKI's (erlotinib, gefitinib, neratinib) in treating patients harboring this mutation before treatment is notably lower. This lack of efficacy can likely be to blame for the poorer prognosis for patients with this mutation as compared to patients with wildtype EGFR or other types of EGFR mutations. Approximately half of EGFR mutant tumors with acquired resistance to TKI inhibition have been shown to harbor this mutation, implicating it as a mechanism of acquired therapy resistence. A third generation TKI (osimertinib) has been approved for the treatment of EGFR T790M mutant NSCLC. Patients positive for T790M in a plasma-based test have similar outcomes like those with tumor biopsy testing.",EGFR TKI Resistance,https://civic.genome.wustl.edu/api/variants/34,34,7,55249071,55249071,C,T,GRCh37,Predictive,D: Preclinical evidence,"Cell line, xenograft, and transgenic models were used to establish Osimertinib as an inhibitor of both EGFR mutation sensitizing (L858M, del exon 19) and T790M resistance mutants. Preclinically, the drug inhibits signaling pathways and cellular growth in both EGFRm(+) and EGFRm(+)/T790M(+) mutant cell lines in vitro, with lower activity against wild-type EGFR lines. Sustained tumor regression was observed in EGFR-mutant tumor xenograft and transgenic models. Treatment of 2 patients with advanced EGFRm(+) T790M(+) NSCLC was reported as proof of principle.",Supports,Sensitivity,Somatic Mutation,accepted,evidence,24893891,"<a href='http://www.ncbi.nlm.nih.gov/pubmed/24893891' target='_blank'>Cross et al., 2014, Cancer Discov</a>",Non-small Cell Lung Carcinoma,3908,http://www.disease-ontology.org/?id=DOID:3908,Osimertinib,NA,3
EGFR,1956,T790M,"EGFR T790M was one of the very first mutations recognized to confer resistance to targeted therapies in non-small cell lung cancer. While successful in amplified EGFR, the efficacy of the first and second generation TKI's (erlotinib, gefitinib, neratinib) in treating patients harboring this mutation before treatment is notably lower. This lack of efficacy can likely be to blame for the poorer prognosis for patients with this mutation as compared to patients with wildtype EGFR or other types of EGFR mutations. Approximately half of EGFR mutant tumors with acquired resistance to TKI inhibition have been shown to harbor this mutation, implicating it as a mechanism of acquired therapy resistence. A third generation TKI (osimertinib) has been approved for the treatment of EGFR T790M mutant NSCLC. Patients positive for T790M in a plasma-based test have similar outcomes like those with tumor biopsy testing.",EGFR TKI Resistance,https://civic.genome.wustl.edu/api/variants/34,34,7,55249071,55249071,C,T,GRCh37,Predictive,B: Clinical evidence,"This phase I/II trial (NCT01802632) involved 253 non-small cell lung cancer patients with activating EGFR mutations, who had progressed on first generation tyrosine kinase inhibitor treatment, and were subsequently treated with Osimertinib (AZD9291). The overall objective tumor response rate was 51%. Among 127 patients with EGFR T790M who could be evaluated for response, the response rate was 61% (95% CI, 52 to 70). In contrast, among 61 patients without EGFR T790M, the response rate was 21% (95% CI, 12 to 34). The median progression-free survival was 9.6 months in EGFR T790M-positive patients and 2.8 months in EGFR T790M-negative patients.",Supports,Sensitivity,Somatic Mutation,accepted,evidence,25923549,"<a href='http://www.ncbi.nlm.nih.gov/pubmed/25923549' target='_blank'>J盲nne et al., 2015, N. Engl. J. Med.</a>",Non-small Cell Lung Carcinoma,3908,http://www.disease-ontology.org/?id=DOID:3908,Osimertinib,NA,4
EGFR,1956,T790M,"EGFR T790M was one of the very first mutations recognized to confer resistance to targeted therapies in non-small cell lung cancer. While successful in amplified EGFR, the efficacy of the first and second generation TKI's (erlotinib, gefitinib, neratinib) in treating patients harboring this mutation before treatment is notably lower. This lack of efficacy can likely be to blame for the poorer prognosis for patients with this mutation as compared to patients with wildtype EGFR or other types of EGFR mutations. Approximately half of EGFR mutant tumors with acquired resistance to TKI inhibition have been shown to harbor this mutation, implicating it as a mechanism of acquired therapy resistence. A third generation TKI (osimertinib) has been approved for the treatment of EGFR T790M mutant NSCLC. Patients positive for T790M in a plasma-based test have similar outcomes like those with tumor biopsy testing.",EGFR TKI Resistance,https://civic.genome.wustl.edu/api/variants/34,34,7,55249071,55249071,C,T,GRCh37,Predictive,B: Clinical evidence,"This study summarized 9 EGFR-mutant patients from two clinical trials involving rociletinib (NCT01526928) and subsequent osimertinib (NCT01802632). 8 were T790M-positive prior to treatment with osimertinib. 6 transitioned directly from rociletinib to osimertinib. 3 patients achieved PR and 4 achieved SD. The median PFS was 208 days (95% CI, 41-208 days). Among 6 patients who transitioned directly from rociletinib to osimertinib all derived clinical benefit from osimertinib with either prolonged SD or PR.",Supports,Sensitivity,Somatic Mutation,accepted,evidence,26720284,"<a href='http://www.ncbi.nlm.nih.gov/pubmed/26720284' target='_blank'>Sequist et al., 2016, JAMA Oncol</a>",Non-small Cell Lung Carcinoma,3908,http://www.disease-ontology.org/?id=DOID:3908,Osimertinib,NA,3
EGFR,1956,T790M,"EGFR T790M was one of the very first mutations recognized to confer resistance to targeted therapies in non-small cell lung cancer. While successful in amplified EGFR, the efficacy of the first and second generation TKI's (erlotinib, gefitinib, neratinib) in treating patients harboring this mutation before treatment is notably lower. This lack of efficacy can likely be to blame for the poorer prognosis for patients with this mutation as compared to patients with wildtype EGFR or other types of EGFR mutations. Approximately half of EGFR mutant tumors with acquired resistance to TKI inhibition have been shown to harbor this mutation, implicating it as a mechanism of acquired therapy resistence. A third generation TKI (osimertinib) has been approved for the treatment of EGFR T790M mutant NSCLC. Patients positive for T790M in a plasma-based test have similar outcomes like those with tumor biopsy testing.",EGFR TKI Resistance,https://civic.genome.wustl.edu/api/variants/34,34,7,55249071,55249071,C,T,GRCh37,Predictive,D: Preclinical evidence,"For cell harboring EGFR T790M mutation, osimertinib and rociletinib showed potent inhibition compared to erlotinib or afatinib. This study performed drug response assays using five human NSCLC cell lines with various combinations of EGFR mutations. In order to directly compare the sensitivity of multiple EGFR mutations to EGFR-TKIs the authors also generated multiple EGFR transduced Ba/F3 stable cell lines and evaluated sensitivity to EGFR-TKIs by MTS assay.",Supports,Sensitivity,Somatic Mutation,accepted,evidence,26515464,"<a href='http://www.ncbi.nlm.nih.gov/pubmed/26515464' target='_blank'>Hirano et al., 2015, Oncotarget</a>",Non-small Cell Lung Carcinoma,3908,http://www.disease-ontology.org/?id=DOID:3908,"Osimertinib, Rociletinib",Substitutes,2
EGFR,1956,T790M,"EGFR T790M was one of the very first mutations recognized to confer resistance to targeted therapies in non-small cell lung cancer. While successful in amplified EGFR, the efficacy of the first and second generation TKI's (erlotinib, gefitinib, neratinib) in treating patients harboring this mutation before treatment is notably lower. This lack of efficacy can likely be to blame for the poorer prognosis for patients with this mutation as compared to patients with wildtype EGFR or other types of EGFR mutations. Approximately half of EGFR mutant tumors with acquired resistance to TKI inhibition have been shown to harbor this mutation, implicating it as a mechanism of acquired therapy resistence. A third generation TKI (osimertinib) has been approved for the treatment of EGFR T790M mutant NSCLC. Patients positive for T790M in a plasma-based test have similar outcomes like those with tumor biopsy testing.",EGFR TKI Resistance,https://civic.genome.wustl.edu/api/variants/34,34,7,55249071,55249071,C,T,GRCh37,Predictive,D: Preclinical evidence,"In an in vitro study, a MCF-7 cell line expressing EGFR L858R and T790M co-mutation demonstrated resistance to erlotinib treatment, compared to MCF-7 cells expressing a known erlotinib sensitizing mutation (EGFR L858R). Sensitivity was determined by assessing YFP signal-EGFR relocation.",Supports,Resistance or Non-Response,Somatic Mutation,submitted,evidence,21132006,"<a href='http://www.ncbi.nlm.nih.gov/pubmed/21132006' target='_blank'>Harada et al., 2011, Oncogene</a>",Non-small Cell Lung Carcinoma,3908,http://www.disease-ontology.org/?id=DOID:3908,Erlotinib,NA,NA
EGFR,1956,T790M,"EGFR T790M was one of the very first mutations recognized to confer resistance to targeted therapies in non-small cell lung cancer. While successful in amplified EGFR, the efficacy of the first and second generation TKI's (erlotinib, gefitinib, neratinib) in treating patients harboring this mutation before treatment is notably lower. This lack of efficacy can likely be to blame for the poorer prognosis for patients with this mutation as compared to patients with wildtype EGFR or other types of EGFR mutations. Approximately half of EGFR mutant tumors with acquired resistance to TKI inhibition have been shown to harbor this mutation, implicating it as a mechanism of acquired therapy resistence. A third generation TKI (osimertinib) has been approved for the treatment of EGFR T790M mutant NSCLC. Patients positive for T790M in a plasma-based test have similar outcomes like those with tumor biopsy testing.",EGFR TKI Resistance,https://civic.genome.wustl.edu/api/variants/34,34,7,55249071,55249071,C,T,GRCh37,Predictive,B: Clinical evidence,"Experimental - Associated drug effects EGFR T790M mutation has been associated with resistance to first generation EGFR tyrosine kinase inhibitors, including erlotinib and gefitinib. In an in vitro study, Ba/F3 cells stably expressing EGFR T790M demonstrated  resistance to gefitinib and erlotinib (greater than 100-fold decreased sensitivity) compared to Ba/F3 expressing wild-type EGFR.",NA,NA,Somatic Mutation,accepted,evidence,19147750,"<a href='http://www.ncbi.nlm.nih.gov/pubmed/19147750' target='_blank'>Kancha et al., 2009, Clin. Cancer Res.</a>",Hematologic Cancer,2531,http://www.disease-ontology.org/?id=DOID:2531,Erlotinib,NA,NA
EGFR,1956,T790M,"EGFR T790M was one of the very first mutations recognized to confer resistance to targeted therapies in non-small cell lung cancer. While successful in amplified EGFR, the efficacy of the first and second generation TKI's (erlotinib, gefitinib, neratinib) in treating patients harboring this mutation before treatment is notably lower. This lack of efficacy can likely be to blame for the poorer prognosis for patients with this mutation as compared to patients with wildtype EGFR or other types of EGFR mutations. Approximately half of EGFR mutant tumors with acquired resistance to TKI inhibition have been shown to harbor this mutation, implicating it as a mechanism of acquired therapy resistence. A third generation TKI (osimertinib) has been approved for the treatment of EGFR T790M mutant NSCLC. Patients positive for T790M in a plasma-based test have similar outcomes like those with tumor biopsy testing.",EGFR TKI Resistance,https://civic.genome.wustl.edu/api/variants/34,34,7,55249071,55249071,C,T,GRCh37,Predictive,D: Preclinical evidence,"In an in vitro study, the recombinant EGFR T790M mutation kinase was associated with reduced sensitivity to bosutinib(IC50: 491nM), as compared to wild-type EGFR kinase (IC50: 53nM). Resistance was assessed by analyzing kinase inhibition.",Supports,Resistance or Non-Response,Somatic Mutation,submitted,evidence,19039322,"<a href='http://www.ncbi.nlm.nih.gov/pubmed/19039322' target='_blank'>Remsing Rix et al., 2009, Leukemia</a>",Chronic Myeloid Leukemia,8552,http://www.disease-ontology.org/?id=DOID:8552,Bosutinib,NA,NA
EGFR,1956,T790M,"EGFR T790M was one of the very first mutations recognized to confer resistance to targeted therapies in non-small cell lung cancer. While successful in amplified EGFR, the efficacy of the first and second generation TKI's (erlotinib, gefitinib, neratinib) in treating patients harboring this mutation before treatment is notably lower. This lack of efficacy can likely be to blame for the poorer prognosis for patients with this mutation as compared to patients with wildtype EGFR or other types of EGFR mutations. Approximately half of EGFR mutant tumors with acquired resistance to TKI inhibition have been shown to harbor this mutation, implicating it as a mechanism of acquired therapy resistence. A third generation TKI (osimertinib) has been approved for the treatment of EGFR T790M mutant NSCLC. Patients positive for T790M in a plasma-based test have similar outcomes like those with tumor biopsy testing.",EGFR TKI Resistance,https://civic.genome.wustl.edu/api/variants/34,34,7,55249071,55249071,C,T,GRCh37,Predictive,B: Clinical evidence,"155 patients with lung adenocarcinomas underwent rebiopsy and genotyping (EGFR, AKT1, BRAF, ERBB2, KRAS, MEK1, NRAS, PIK3CA and FISH for MET and HER2) after the development of acquired resistance to EGFR inhibitors (gefitinib or erlotinib). 98 patients were found to have developed EGFR T790M mutations.",Supports,Resistance or Non-Response,Somatic Mutation,accepted,evidence,23470965,"<a href='http://www.ncbi.nlm.nih.gov/pubmed/23470965' target='_blank'>Yu et al., 2013, Clin. Cancer Res.</a>",Lung Adenocarcinoma,3910,http://www.disease-ontology.org/?id=DOID:3910,"Gefitinib, Erlotinib",Substitutes,3
EGFR,1956,T790M,"EGFR T790M was one of the very first mutations recognized to confer resistance to targeted therapies in non-small cell lung cancer. While successful in amplified EGFR, the efficacy of the first and second generation TKI's (erlotinib, gefitinib, neratinib) in treating patients harboring this mutation before treatment is notably lower. This lack of efficacy can likely be to blame for the poorer prognosis for patients with this mutation as compared to patients with wildtype EGFR or other types of EGFR mutations. Approximately half of EGFR mutant tumors with acquired resistance to TKI inhibition have been shown to harbor this mutation, implicating it as a mechanism of acquired therapy resistence. A third generation TKI (osimertinib) has been approved for the treatment of EGFR T790M mutant NSCLC. Patients positive for T790M in a plasma-based test have similar outcomes like those with tumor biopsy testing.",EGFR TKI Resistance,https://civic.genome.wustl.edu/api/variants/34,34,7,55249071,55249071,C,T,GRCh37,Predictive,D: Preclinical evidence,CO-1686 (Rociletinib) more effectively induced apoptosis in EGFR mutated (T790M and others) NSCLC cell lines than those harboring wildtype EGFR. CO-1686 also more effectively reduced tumor volume of mouse xenografts harboring the T790M than those with wildtype EGFR.,Supports,Sensitivity,Somatic Mutation,accepted,evidence,24065731,"<a href='http://www.ncbi.nlm.nih.gov/pubmed/24065731' target='_blank'>Walter et al., 2013, Cancer Discov</a>",Non-small Cell Lung Carcinoma,3908,http://www.disease-ontology.org/?id=DOID:3908,Rociletinib,NA,3
EGFR,1956,T790M,"EGFR T790M was one of the very first mutations recognized to confer resistance to targeted therapies in non-small cell lung cancer. While successful in amplified EGFR, the efficacy of the first and second generation TKI's (erlotinib, gefitinib, neratinib) in treating patients harboring this mutation before treatment is notably lower. This lack of efficacy can likely be to blame for the poorer prognosis for patients with this mutation as compared to patients with wildtype EGFR or other types of EGFR mutations. Approximately half of EGFR mutant tumors with acquired resistance to TKI inhibition have been shown to harbor this mutation, implicating it as a mechanism of acquired therapy resistence. A third generation TKI (osimertinib) has been approved for the treatment of EGFR T790M mutant NSCLC. Patients positive for T790M in a plasma-based test have similar outcomes like those with tumor biopsy testing.",EGFR TKI Resistance,https://civic.genome.wustl.edu/api/variants/34,34,7,55249071,55249071,C,T,GRCh37,Predictive,A: Validated,Osimertinib has been approved for the treatment of EGFR T790M mutant NSCLC.,Supports,Sensitivity,Somatic Mutation,accepted,evidence,26729184,"<a href='http://www.ncbi.nlm.nih.gov/pubmed/26729184' target='_blank'>Greig, 2016, Drugs</a>",Non-small Cell Lung Carcinoma,3908,http://www.disease-ontology.org/?id=DOID:3908,Osimertinib,NA,5
EGFR,1956,T790M,"EGFR T790M was one of the very first mutations recognized to confer resistance to targeted therapies in non-small cell lung cancer. While successful in amplified EGFR, the efficacy of the first and second generation TKI's (erlotinib, gefitinib, neratinib) in treating patients harboring this mutation before treatment is notably lower. This lack of efficacy can likely be to blame for the poorer prognosis for patients with this mutation as compared to patients with wildtype EGFR or other types of EGFR mutations. Approximately half of EGFR mutant tumors with acquired resistance to TKI inhibition have been shown to harbor this mutation, implicating it as a mechanism of acquired therapy resistence. A third generation TKI (osimertinib) has been approved for the treatment of EGFR T790M mutant NSCLC. Patients positive for T790M in a plasma-based test have similar outcomes like those with tumor biopsy testing.",EGFR TKI Resistance,https://civic.genome.wustl.edu/api/variants/34,34,7,55249071,55249071,C,T,GRCh37,Predictive,B: Clinical evidence,"48 tumor samples from 41 patients with EGFR mutant lung adenocarcinoma that were resistant to tyrosine kinase inhibition underwent next generation sequencing (NGS failed in 5 samples leading to a remaining 43 specimens from 39 patients). The prevalence of various mutations post-treatment was analyzed. 79%, or 31 out of the 39 patients,  had the T790M EGFR mutation present, indicating its importance in the development of resistance.",Supports,Resistance or Non-Response,Somatic Mutation,accepted,evidence,27304188,"<a href='http://www.ncbi.nlm.nih.gov/pubmed/27304188' target='_blank'>Belchis et al., 2016, Oncotarget</a>",Non-small Cell Lung Carcinoma,3908,http://www.disease-ontology.org/?id=DOID:3908,"Gefitinib, Erlotinib, Afatinib",Substitutes,3
EGFR,1956,T790M,"EGFR T790M was one of the very first mutations recognized to confer resistance to targeted therapies in non-small cell lung cancer. While successful in amplified EGFR, the efficacy of the first and second generation TKI's (erlotinib, gefitinib, neratinib) in treating patients harboring this mutation before treatment is notably lower. This lack of efficacy can likely be to blame for the poorer prognosis for patients with this mutation as compared to patients with wildtype EGFR or other types of EGFR mutations. Approximately half of EGFR mutant tumors with acquired resistance to TKI inhibition have been shown to harbor this mutation, implicating it as a mechanism of acquired therapy resistence. A third generation TKI (osimertinib) has been approved for the treatment of EGFR T790M mutant NSCLC. Patients positive for T790M in a plasma-based test have similar outcomes like those with tumor biopsy testing.",EGFR TKI Resistance,https://civic.genome.wustl.edu/api/variants/34,34,7,55249071,55249071,C,T,GRCh37,Predictive,C: Case study,"Case report of a patient with stage IV lung adenocarcinoma and a 15鈥揵ase pair deletion in EGFR exon 19. Partial response with erlotinib was achieved for 15 months after initial chemotherapy. After further progression, rebiopsy additionally identified the EGFR T790M mutation and the patient received several cycles of chemotherapy and targeted therapy including afatinib, cetuximab, erlotinib, AZD9291. She was treated with AZD9291 for 9 months until disease progression.",Supports,Sensitivity,Somatic Mutation,accepted,evidence,26181354,"<a href='http://www.ncbi.nlm.nih.gov/pubmed/26181354' target='_blank'>Yu et al., 2015, JAMA Oncol</a>",Lung Adenocarcinoma,3910,http://www.disease-ontology.org/?id=DOID:3910,Osimertinib,NA,1
EGFR,1956,T790M,"EGFR T790M was one of the very first mutations recognized to confer resistance to targeted therapies in non-small cell lung cancer. While successful in amplified EGFR, the efficacy of the first and second generation TKI's (erlotinib, gefitinib, neratinib) in treating patients harboring this mutation before treatment is notably lower. This lack of efficacy can likely be to blame for the poorer prognosis for patients with this mutation as compared to patients with wildtype EGFR or other types of EGFR mutations. Approximately half of EGFR mutant tumors with acquired resistance to TKI inhibition have been shown to harbor this mutation, implicating it as a mechanism of acquired therapy resistence. A third generation TKI (osimertinib) has been approved for the treatment of EGFR T790M mutant NSCLC. Patients positive for T790M in a plasma-based test have similar outcomes like those with tumor biopsy testing.",EGFR TKI Resistance,https://civic.genome.wustl.edu/api/variants/34,34,7,55249071,55249071,C,T,GRCh37,Predictive,B: Clinical evidence,"Patients with advanced NSCLC and acquired resistance to EGFR TKI (gefitinib or erlotinib) were analyzed for T790M mutations.  Of the 70 patients analyzed, 36 (51%) had the T790M mutation and 34 (49%) were T790M-negative.  There was no significant difference in the median post-progression or overall survival between patients with T790M mutation and without T790M mutation for initial TKI treatment.  However, subsequent treatment with afatinib showed partial response in six patients where 1/21(5%) were in the T790M-positive group and 5/13 (38%) were in the T790M-negative group (P=0.01).",Supports,Resistance or Non-Response,Somatic Mutation,accepted,evidence,24035188,"<a href='http://www.ncbi.nlm.nih.gov/pubmed/24035188' target='_blank'>Sun et al., 2013, Lung Cancer</a>",Non-small Cell Lung Carcinoma,3908,http://www.disease-ontology.org/?id=DOID:3908,Afatinib,NA,4
EGFR,1956,T790M,"EGFR T790M was one of the very first mutations recognized to confer resistance to targeted therapies in non-small cell lung cancer. While successful in amplified EGFR, the efficacy of the first and second generation TKI's (erlotinib, gefitinib, neratinib) in treating patients harboring this mutation before treatment is notably lower. This lack of efficacy can likely be to blame for the poorer prognosis for patients with this mutation as compared to patients with wildtype EGFR or other types of EGFR mutations. Approximately half of EGFR mutant tumors with acquired resistance to TKI inhibition have been shown to harbor this mutation, implicating it as a mechanism of acquired therapy resistence. A third generation TKI (osimertinib) has been approved for the treatment of EGFR T790M mutant NSCLC. Patients positive for T790M in a plasma-based test have similar outcomes like those with tumor biopsy testing.",EGFR TKI Resistance,https://civic.genome.wustl.edu/api/variants/34,34,7,55249071,55249071,C,T,GRCh37,Predictive,A: Validated,"Randomized, international, open-label, phase 3 trial (NCT02151981) in 419 patients with T790M-positive advanced NSCLC and disease progression after first-line EGFR-TKI therapy. Patients were randomized, in a 2:1 ratio, to oral osimertinib or chemotherapy (pemetrexed plus either carboplatin or cisplatin every 3 weeks for up to six cycles, maintenance pemetrexed was allowed). Primary end point was PFS, which was significantly longer with osimertinib than with chemotherapy (10.1 months vs. 4.4 months; HR 0.30; 95% CI: 0.23 to 0.41; P<0.001). Objective response rate was significantly better with osimertinib (71%; 95% CI, 65 to 76) than with chemotherapy (31%; 95% CI, 24 to 40) (odds ratio for objective response, 5.39; 95% CI, 3.47 to 8.48; P<0.001).",Supports,Sensitivity,Somatic Mutation,accepted,evidence,27959700,"<a href='http://www.ncbi.nlm.nih.gov/pubmed/27959700' target='_blank'>Mok et al., 2016, N. Engl. J. Med.</a>",Non-small Cell Lung Carcinoma,3908,http://www.disease-ontology.org/?id=DOID:3908,Osimertinib,NA,5
EGFR,1956,T790M,"EGFR T790M was one of the very first mutations recognized to confer resistance to targeted therapies in non-small cell lung cancer. While successful in amplified EGFR, the efficacy of the first and second generation TKI's (erlotinib, gefitinib, neratinib) in treating patients harboring this mutation before treatment is notably lower. This lack of efficacy can likely be to blame for the poorer prognosis for patients with this mutation as compared to patients with wildtype EGFR or other types of EGFR mutations. Approximately half of EGFR mutant tumors with acquired resistance to TKI inhibition have been shown to harbor this mutation, implicating it as a mechanism of acquired therapy resistence. A third generation TKI (osimertinib) has been approved for the treatment of EGFR T790M mutant NSCLC. Patients positive for T790M in a plasma-based test have similar outcomes like those with tumor biopsy testing.",EGFR TKI Resistance,https://civic.genome.wustl.edu/api/variants/34,34,7,55249071,55249071,C,T,GRCh37,Predictive,C: Case study,"In a lung adenocarcinoma patient harboring an EGFR E746_A750 mutation and an acquired EGFR T790M co-mutation, EGFR T790M was associated with sensitivity to osimertinib monotherapy. Prior to the development of the EGFR T790M mutation, the patient was treated with gefitinib and achieved a partial response, but subsequently tumor progression occurred; however, osimertinib treatment resulted a favorable tumor response with the extinguishment of the EGFR T790M mutation. In a stage IV lung adenocarcinoma patient harboring an EGFR L858R mutation and an acquired EGFR T790M co-mutation, EGFR T790M was associated with sensitivity to osimertinib monotherapy. Prior to the development of the EGFR T790M mutation, the patient was treated with erlotinib, followed by gefitinib for 12 months and achieved stable disease, but subsequently metastasis occurred; the EGFR T790M was then identified and subsequent 10 month treatment with osimertinib monotherapy resulted in a 45% disease regression.",Supports,Sensitivity,Somatic Mutation,accepted,evidence,26269204,"<a href='http://www.ncbi.nlm.nih.gov/pubmed/26269204' target='_blank'>Planchard et al., 2015, Ann. Oncol.</a>",Lung Adenocarcinoma,3910,http://www.disease-ontology.org/?id=DOID:3910,Osimertinib,NA,2
EGFR,1956,T790M,"EGFR T790M was one of the very first mutations recognized to confer resistance to targeted therapies in non-small cell lung cancer. While successful in amplified EGFR, the efficacy of the first and second generation TKI's (erlotinib, gefitinib, neratinib) in treating patients harboring this mutation before treatment is notably lower. This lack of efficacy can likely be to blame for the poorer prognosis for patients with this mutation as compared to patients with wildtype EGFR or other types of EGFR mutations. Approximately half of EGFR mutant tumors with acquired resistance to TKI inhibition have been shown to harbor this mutation, implicating it as a mechanism of acquired therapy resistence. A third generation TKI (osimertinib) has been approved for the treatment of EGFR T790M mutant NSCLC. Patients positive for T790M in a plasma-based test have similar outcomes like those with tumor biopsy testing.",EGFR TKI Resistance,https://civic.genome.wustl.edu/api/variants/34,34,7,55249071,55249071,C,T,GRCh37,Predictive,C: Case study,"In a study of 6 patients with progressive non-small cell lung cancer during gefitinib or erlotinib therapy,  comparison of DNA sequences from the original diagnostic biopsy specimen and the second biopsy specimen demonstrated that 2 patients acquired a new EGFR-T790M mutation.",Supports,Resistance or Non-Response,Somatic Mutation,accepted,evidence,15737014,"<a href='http://www.ncbi.nlm.nih.gov/pubmed/15737014' target='_blank'>Pao et al., 2005, PLoS Med.</a>",Non-small Cell Lung Carcinoma,3908,http://www.disease-ontology.org/?id=DOID:3908,Gefitinib,NA,NA
EGFR,1956,T790M,"EGFR T790M was one of the very first mutations recognized to confer resistance to targeted therapies in non-small cell lung cancer. While successful in amplified EGFR, the efficacy of the first and second generation TKI's (erlotinib, gefitinib, neratinib) in treating patients harboring this mutation before treatment is notably lower. This lack of efficacy can likely be to blame for the poorer prognosis for patients with this mutation as compared to patients with wildtype EGFR or other types of EGFR mutations. Approximately half of EGFR mutant tumors with acquired resistance to TKI inhibition have been shown to harbor this mutation, implicating it as a mechanism of acquired therapy resistence. A third generation TKI (osimertinib) has been approved for the treatment of EGFR T790M mutant NSCLC. Patients positive for T790M in a plasma-based test have similar outcomes like those with tumor biopsy testing.",EGFR TKI Resistance,https://civic.genome.wustl.edu/api/variants/34,34,7,55249071,55249071,C,T,GRCh37,Predictive,C: Case study,"In a study of 14 patients with progressive non-small cell lung cancer during gefitinib,  comparison of DNA sequences from the original diagnostic biopsy specimen and the second biopsy specimen demonstrated that 7 patients acquired a new EGFR-T790M mutation.",Supports,Resistance or Non-Response,Somatic Mutation,accepted,evidence,17020982,"<a href='http://www.ncbi.nlm.nih.gov/pubmed/17020982' target='_blank'>Kosaka et al., 2006, Clin. Cancer Res.</a>",Non-small Cell Lung Carcinoma,3908,http://www.disease-ontology.org/?id=DOID:3908,Gefitinib,NA,NA
EGFR,1956,T790M,"EGFR T790M was one of the very first mutations recognized to confer resistance to targeted therapies in non-small cell lung cancer. While successful in amplified EGFR, the efficacy of the first and second generation TKI's (erlotinib, gefitinib, neratinib) in treating patients harboring this mutation before treatment is notably lower. This lack of efficacy can likely be to blame for the poorer prognosis for patients with this mutation as compared to patients with wildtype EGFR or other types of EGFR mutations. Approximately half of EGFR mutant tumors with acquired resistance to TKI inhibition have been shown to harbor this mutation, implicating it as a mechanism of acquired therapy resistence. A third generation TKI (osimertinib) has been approved for the treatment of EGFR T790M mutant NSCLC. Patients positive for T790M in a plasma-based test have similar outcomes like those with tumor biopsy testing.",EGFR TKI Resistance,https://civic.genome.wustl.edu/api/variants/34,34,7,55249071,55249071,C,T,GRCh37,Predictive,D: Preclinical evidence,"In an in vitro study using NCI-H1666 cells (wildtype EGFR) and NCI-H1975 cells (EGFR-L858R/T790M), inhibition of cell growth was used as an assay to determine sensitivity to reversible tyrosine kinase inhibitor drugs. Cells with an EGFR L858R/T790M mutation demonstrated a reduced response to lapatinib (IC50: >4000nM vs. 534nM) compared to wildtype EGFR cells. Similarly, NIH-3T3 ectopically expression EGFR-L858R/T790M showed reduced sensistivity to lapatinib compared to EGFR wt or L585R mutant cells. These results were further confirmed in a Ba/F3 cell line model",Supports,Resistance or Non-Response,Somatic Mutation,accepted,evidence,18408761,"<a href='http://www.ncbi.nlm.nih.gov/pubmed/18408761' target='_blank'>Li et al., 2008, Oncogene</a>",Non-small Cell Lung Carcinoma,3908,http://www.disease-ontology.org/?id=DOID:3908,Lapatinib,NA,4
EGFR,1956,T790M,"EGFR T790M was one of the very first mutations recognized to confer resistance to targeted therapies in non-small cell lung cancer. While successful in amplified EGFR, the efficacy of the first and second generation TKI's (erlotinib, gefitinib, neratinib) in treating patients harboring this mutation before treatment is notably lower. This lack of efficacy can likely be to blame for the poorer prognosis for patients with this mutation as compared to patients with wildtype EGFR or other types of EGFR mutations. Approximately half of EGFR mutant tumors with acquired resistance to TKI inhibition have been shown to harbor this mutation, implicating it as a mechanism of acquired therapy resistence. A third generation TKI (osimertinib) has been approved for the treatment of EGFR T790M mutant NSCLC. Patients positive for T790M in a plasma-based test have similar outcomes like those with tumor biopsy testing.",EGFR TKI Resistance,https://civic.genome.wustl.edu/api/variants/34,34,7,55249071,55249071,C,T,GRCh37,Predictive,D: Preclinical evidence,"In an in vitro study using NCI-H322 cells (wildtype EGFR) and NCI-H1975 cells (EGFR-L858R/T790M), inhibition of cell growth was used as an assay to determine sensitivity to irreversible tyrosine kinase inhibitor (TKI) drugs. PF00299804 inhibited the growth of Ba/F3 cell lines containing the EFGR T790M resistance mutation as well as H1975 and H3255 cell lines that contain both EGFR L858R and T790M mutations and H820 containing an EGFR exon 19 deletion (Del 747_L751, Ins S) and a T790M mutation. All three cell lines were resistant to gefitinib in vitro, but sensitive to PF00299804 (IC50 <1 渭mol/L for all three cell lines).",Supports,Sensitivity,Somatic Mutation,accepted,evidence,18089823,"<a href='http://www.ncbi.nlm.nih.gov/pubmed/18089823' target='_blank'>Engelman et al., 2007, Cancer Res.</a>",Non-small Cell Lung Carcinoma,3908,http://www.disease-ontology.org/?id=DOID:3908,PF 00299804,NA,3
EGFR,1956,T790M,"EGFR T790M was one of the very first mutations recognized to confer resistance to targeted therapies in non-small cell lung cancer. While successful in amplified EGFR, the efficacy of the first and second generation TKI's (erlotinib, gefitinib, neratinib) in treating patients harboring this mutation before treatment is notably lower. This lack of efficacy can likely be to blame for the poorer prognosis for patients with this mutation as compared to patients with wildtype EGFR or other types of EGFR mutations. Approximately half of EGFR mutant tumors with acquired resistance to TKI inhibition have been shown to harbor this mutation, implicating it as a mechanism of acquired therapy resistence. A third generation TKI (osimertinib) has been approved for the treatment of EGFR T790M mutant NSCLC. Patients positive for T790M in a plasma-based test have similar outcomes like those with tumor biopsy testing.",EGFR TKI Resistance,https://civic.genome.wustl.edu/api/variants/34,34,7,55249071,55249071,C,T,GRCh37,Predictive,D: Preclinical evidence,"The NSCLC cell line NCI-H1975 carrying the EGFR T790M mutation was resistant to erlotinib but showed increased sensitivity to HKI-272 (neratinib, IC50: 0.29 渭mol/L).In an in vitro study Ba/F3 cells transfected with either EGFR-L858R or EGFR-L858R/T790M were used to assay cell growth. Ba/F3 cells require IL-3 in order to proliferate, but cells transfected with an activated oncogene are IL-3 independent. Cells with an EGFR L858R/T790M mutation demonstrated an improved response to neratinib (IC50: 0.185umol/L vs. >10umol/L) compared to the same cells treated with erlotinib.",Supports,Sensitivity,Somatic Mutation,accepted,evidence,16818618,"<a href='http://www.ncbi.nlm.nih.gov/pubmed/16818618' target='_blank'>Shimamura et al., 2006, Cancer Res.</a>",Non-small Cell Lung Carcinoma,3908,http://www.disease-ontology.org/?id=DOID:3908,Neratinib,NA,2
EGFR,1956,T790M,"EGFR T790M was one of the very first mutations recognized to confer resistance to targeted therapies in non-small cell lung cancer. While successful in amplified EGFR, the efficacy of the first and second generation TKI's (erlotinib, gefitinib, neratinib) in treating patients harboring this mutation before treatment is notably lower. This lack of efficacy can likely be to blame for the poorer prognosis for patients with this mutation as compared to patients with wildtype EGFR or other types of EGFR mutations. Approximately half of EGFR mutant tumors with acquired resistance to TKI inhibition have been shown to harbor this mutation, implicating it as a mechanism of acquired therapy resistence. A third generation TKI (osimertinib) has been approved for the treatment of EGFR T790M mutant NSCLC. Patients positive for T790M in a plasma-based test have similar outcomes like those with tumor biopsy testing.",EGFR TKI Resistance,https://civic.genome.wustl.edu/api/variants/34,34,7,55249071,55249071,C,T,GRCh37,Predictive,D: Preclinical evidence,"In an in vitro study using NCI-H1666 cells (wildtype EGFR) and NCI-H1975 cells (EGFR-L858R/T790M), inhibition of cell growth was used as an assay to determine sensitivity to tyrosine kinase inhibitor (TKI) drugs. Cells with an EGFR L858R/T790M mutation demonstrated an improved response to afatinib (IC50: 99nM vs. >4000nM) compared to the same cells treated with erlotinib. In an in vivo mouse xenograft study, the growth of cells with an EGFR-L858R/T790M mutation were more sensitive to treatment of afatinib (concentration: 15-20mg/kg) (median tumor volume = 75-150mm^3 vs. 1000mm^3), compared to reversible TKI lapatinib-treated xenografts. However, no complete responses were observed with afatinib alone.",Supports,Sensitivity,Somatic Mutation,accepted,evidence,18408761,"<a href='http://www.ncbi.nlm.nih.gov/pubmed/18408761' target='_blank'>Li et al., 2008, Oncogene</a>",Non-small Cell Lung Carcinoma,3908,http://www.disease-ontology.org/?id=DOID:3908,Afatinib,NA,2
EGFR,1956,T790M,"EGFR T790M was one of the very first mutations recognized to confer resistance to targeted therapies in non-small cell lung cancer. While successful in amplified EGFR, the efficacy of the first and second generation TKI's (erlotinib, gefitinib, neratinib) in treating patients harboring this mutation before treatment is notably lower. This lack of efficacy can likely be to blame for the poorer prognosis for patients with this mutation as compared to patients with wildtype EGFR or other types of EGFR mutations. Approximately half of EGFR mutant tumors with acquired resistance to TKI inhibition have been shown to harbor this mutation, implicating it as a mechanism of acquired therapy resistence. A third generation TKI (osimertinib) has been approved for the treatment of EGFR T790M mutant NSCLC. Patients positive for T790M in a plasma-based test have similar outcomes like those with tumor biopsy testing.",EGFR TKI Resistance,https://civic.genome.wustl.edu/api/variants/34,34,7,55249071,55249071,C,T,GRCh37,Predictive,D: Preclinical evidence,"In an in vitro study using purified EGFR protein, kinase activity was assayed and compared for wildtype EGFR, EGFR-T790M and EGFR-T790M/L858R using both reversible and irreversible TKI drugs. EFGR proteins with T790M or T790M/L858R mutations were more sensitive to afatinib treatment (IC50: 9.8nM and 24nM, respectively vs. IC50: >1000nM and >1000nM, respectively) compared to treatment with erlotinib or lapatinib treatment. In an in vitro study using NCI-H358 cells (wildtype EGFR) and NCI-H1975 cells (EGFR-L858R/T790M), inhibition of cell growth was used as an assay to determine sensitivity to tyrosine kinase inhibitor drugs. Cells with an EGFR L858R/T790M mutation demonstrated an improved response to afatinib (GI50: 42.0nM vs. >1000nM) compared to the same cells treated with erlotinib. However, IC50s were intermediate compared to a more potent pan-HER inhibitor.",Supports,Sensitivity,Somatic Mutation,accepted,evidence,21732342,"<a href='http://www.ncbi.nlm.nih.gov/pubmed/21732342' target='_blank'>Cha et al., 2012, Int. J. Cancer</a>",Non-small Cell Lung Carcinoma,3908,http://www.disease-ontology.org/?id=DOID:3908,Afatinib,NA,2
EGFR,1956,T790M,"EGFR T790M was one of the very first mutations recognized to confer resistance to targeted therapies in non-small cell lung cancer. While successful in amplified EGFR, the efficacy of the first and second generation TKI's (erlotinib, gefitinib, neratinib) in treating patients harboring this mutation before treatment is notably lower. This lack of efficacy can likely be to blame for the poorer prognosis for patients with this mutation as compared to patients with wildtype EGFR or other types of EGFR mutations. Approximately half of EGFR mutant tumors with acquired resistance to TKI inhibition have been shown to harbor this mutation, implicating it as a mechanism of acquired therapy resistence. A third generation TKI (osimertinib) has been approved for the treatment of EGFR T790M mutant NSCLC. Patients positive for T790M in a plasma-based test have similar outcomes like those with tumor biopsy testing.",EGFR TKI Resistance,https://civic.genome.wustl.edu/api/variants/34,34,7,55249071,55249071,C,T,GRCh37,Predictive,D: Preclinical evidence,"In an in vitro study using NCI-H1666 cells (wildtype EGFR) and NCI-H1975 cells (EGFR-L858R/T790M), inhibition of cell growth was used as an assay to determine sensitivity to tyrosine kinase inhibitor (TKI) drugs. Cells with an EGFR L858R/T790M mutation demonstrated an improved response to canertinib (IC50: 101nM vs. >4000nM) compared to the same cells treated with erlotinib. IC50 values of canertinib were comparable to afatinib.",Supports,Sensitivity,Somatic Mutation,accepted,evidence,18408761,"<a href='http://www.ncbi.nlm.nih.gov/pubmed/18408761' target='_blank'>Li et al., 2008, Oncogene</a>",Non-small Cell Lung Carcinoma,3908,http://www.disease-ontology.org/?id=DOID:3908,Canertinib,NA,2
EGFR,1956,T790M,"EGFR T790M was one of the very first mutations recognized to confer resistance to targeted therapies in non-small cell lung cancer. While successful in amplified EGFR, the efficacy of the first and second generation TKI's (erlotinib, gefitinib, neratinib) in treating patients harboring this mutation before treatment is notably lower. This lack of efficacy can likely be to blame for the poorer prognosis for patients with this mutation as compared to patients with wildtype EGFR or other types of EGFR mutations. Approximately half of EGFR mutant tumors with acquired resistance to TKI inhibition have been shown to harbor this mutation, implicating it as a mechanism of acquired therapy resistence. A third generation TKI (osimertinib) has been approved for the treatment of EGFR T790M mutant NSCLC. Patients positive for T790M in a plasma-based test have similar outcomes like those with tumor biopsy testing.",EGFR TKI Resistance,https://civic.genome.wustl.edu/api/variants/34,34,7,55249071,55249071,C,T,GRCh37,Predictive,B: Clinical evidence,"In a prospective study (NCT01802632) of 253 locally advanced or metastatic, non-small cell lung cancer patients, patients with EGFR T790M mutations treated with osimertinib were associated with improved progression free survival (9.6mo, 95% CI:8.3-not reached vs. 2.8mo, 95% CI: 2.4-4.3), improved objective response rate (61% (78/127), 95% CI: 52-70 vs. 21% (37/61), 95% CI:12-34) and improved disease control rate (95% (121/127), 95% CI:90-98 vs. 61%, (37/61), 95% CI: 47-73), as compared to patients that did not harbor EGFR T790M mutations.",Supports,Sensitivity,Somatic Mutation,rejected,evidence,25923549,"<a href='http://www.ncbi.nlm.nih.gov/pubmed/25923549' target='_blank'>J盲nne et al., 2015, N. Engl. J. Med.</a>",Non-small Cell Lung Carcinoma,3908,http://www.disease-ontology.org/?id=DOID:3908,Mereletinib,NA,NA
EGFR,1956,T790M,"EGFR T790M was one of the very first mutations recognized to confer resistance to targeted therapies in non-small cell lung cancer. While successful in amplified EGFR, the efficacy of the first and second generation TKI's (erlotinib, gefitinib, neratinib) in treating patients harboring this mutation before treatment is notably lower. This lack of efficacy can likely be to blame for the poorer prognosis for patients with this mutation as compared to patients with wildtype EGFR or other types of EGFR mutations. Approximately half of EGFR mutant tumors with acquired resistance to TKI inhibition have been shown to harbor this mutation, implicating it as a mechanism of acquired therapy resistence. A third generation TKI (osimertinib) has been approved for the treatment of EGFR T790M mutant NSCLC. Patients positive for T790M in a plasma-based test have similar outcomes like those with tumor biopsy testing.",EGFR TKI Resistance,https://civic.genome.wustl.edu/api/variants/34,34,7,55249071,55249071,C,T,GRCh37,Predictive,D: Preclinical evidence,"Currently, there are no effective therapeutic strategies to overcome the C797S/T790M/activating-mutation (triple-mutation)-mediated EGFR-TKI resistance to Osimertinib. In the present study, we identify brigatinib to be effective against triple-mutation-harbouring cells in vitro and in vivo. The efficacy of brigatinib is enhanced markedly by combination with anti-EGFR antibodies Ceutximab or Panitumumab because of the decrease of surface and total EGFR expression. Thus, the combination therapy of brigatinib with anti-EGFR antibody is a powerful candidate to overcome triple-mutant EGFR.",Supports,Sensitivity,Somatic Mutation,submitted,evidence,28287083,"<a href='http://www.ncbi.nlm.nih.gov/pubmed/28287083' target='_blank'>Uchibori et al., 2017, Nat Commun</a>",Non-small Cell Lung Carcinoma,3908,http://www.disease-ontology.org/?id=DOID:3908,"Brigatinib, Panitumumab, Cetuximab",NA,4
EGFR,1956,T790M,"EGFR T790M was one of the very first mutations recognized to confer resistance to targeted therapies in non-small cell lung cancer. While successful in amplified EGFR, the efficacy of the first and second generation TKI's (erlotinib, gefitinib, neratinib) in treating patients harboring this mutation before treatment is notably lower. This lack of efficacy can likely be to blame for the poorer prognosis for patients with this mutation as compared to patients with wildtype EGFR or other types of EGFR mutations. Approximately half of EGFR mutant tumors with acquired resistance to TKI inhibition have been shown to harbor this mutation, implicating it as a mechanism of acquired therapy resistence. A third generation TKI (osimertinib) has been approved for the treatment of EGFR T790M mutant NSCLC. Patients positive for T790M in a plasma-based test have similar outcomes like those with tumor biopsy testing.",EGFR TKI Resistance,https://civic.genome.wustl.edu/api/variants/34,34,7,55249071,55249071,C,T,GRCh37,Predictive,B: Clinical evidence,"Recently, the development of the third-generation epidermal growth factor receptor-small molecule inhibitor (EGFR-TKI) rociletinib had failed. in May 2016, after receiving a negative reply from  the  FDA鈥檚  Oncologic  Drugs  Advisory  Committee, which voted 12鈥? against the accelerated approval of rociletinib, Clovis Oncology decided to end the development of rociletinib.In this review, the wide-ranging aspects of the evolution of EGFR-TKIs were collected, with a special focus on rociletinib.",Does Not Support,Sensitivity,Somatic Mutation,submitted,evidence,27785053,"<a href='http://www.ncbi.nlm.nih.gov/pubmed/27785053' target='_blank'>Van Der Steen et al., 2016, Onco Targets Ther</a>",Non-small Cell Lung Carcinoma,3908,http://www.disease-ontology.org/?id=DOID:3908,Rociletinib,NA,4
EGFR,1956,T790M,"EGFR T790M was one of the very first mutations recognized to confer resistance to targeted therapies in non-small cell lung cancer. While successful in amplified EGFR, the efficacy of the first and second generation TKI's (erlotinib, gefitinib, neratinib) in treating patients harboring this mutation before treatment is notably lower. This lack of efficacy can likely be to blame for the poorer prognosis for patients with this mutation as compared to patients with wildtype EGFR or other types of EGFR mutations. Approximately half of EGFR mutant tumors with acquired resistance to TKI inhibition have been shown to harbor this mutation, implicating it as a mechanism of acquired therapy resistence. A third generation TKI (osimertinib) has been approved for the treatment of EGFR T790M mutant NSCLC. Patients positive for T790M in a plasma-based test have similar outcomes like those with tumor biopsy testing.",EGFR TKI Resistance,https://civic.genome.wustl.edu/api/variants/34,34,7,55249071,55249071,C,T,GRCh37,Prognostic,B: Clinical evidence,Patients with NSCLC harboring EGFR T790M mutation have statistically worse overall survival compared to patients with L858R or other exon 19 activating mutations.,Supports,Poor Outcome,Somatic Mutation,accepted,evidence,24729716,"<a href='http://www.ncbi.nlm.nih.gov/pubmed/24729716' target='_blank'>Li et al., 2014, Onco Targets Ther</a>",Non-small Cell Lung Carcinoma,3908,http://www.disease-ontology.org/?id=DOID:3908,NA,NA,4
EGFR,1956,T790M,"EGFR T790M was one of the very first mutations recognized to confer resistance to targeted therapies in non-small cell lung cancer. While successful in amplified EGFR, the efficacy of the first and second generation TKI's (erlotinib, gefitinib, neratinib) in treating patients harboring this mutation before treatment is notably lower. This lack of efficacy can likely be to blame for the poorer prognosis for patients with this mutation as compared to patients with wildtype EGFR or other types of EGFR mutations. Approximately half of EGFR mutant tumors with acquired resistance to TKI inhibition have been shown to harbor this mutation, implicating it as a mechanism of acquired therapy resistence. A third generation TKI (osimertinib) has been approved for the treatment of EGFR T790M mutant NSCLC. Patients positive for T790M in a plasma-based test have similar outcomes like those with tumor biopsy testing.",EGFR TKI Resistance,https://civic.genome.wustl.edu/api/variants/34,34,7,55249071,55249071,C,T,GRCh37,Prognostic,B: Clinical evidence,"In NSCLC patients with T790M and another activating mutations, their progression free survival is shorter compared to those who do not possess T790M mutation.",Supports,Poor Outcome,Somatic Mutation,accepted,evidence,24623981,"<a href='http://www.ncbi.nlm.nih.gov/pubmed/24623981' target='_blank'>Ding et al., 2014, Onco Targets Ther</a>",Non-small Cell Lung Carcinoma,3908,http://www.disease-ontology.org/?id=DOID:3908,NA,NA,4
EGFR,1956,AMPLIFICATION,NA,NA,https://civic.genome.wustl.edu/api/variants/190,190,7,55086794,55279321,NA,NA,GRCh37,Prognostic,B: Clinical evidence,"In patients with cervical squamous cell carcinoma, those with gene amplification of EGFR had worse overall survival.",Supports,Poor Outcome,Somatic Mutation,accepted,evidence,21730982,"<a href='http://www.ncbi.nlm.nih.gov/pubmed/21730982' target='_blank'>Iida et al., 2011, Br. J. Cancer</a>",Cervical Squamous Cell Carcinoma,3744,http://www.disease-ontology.org/?id=DOID:3744,NA,NA,3
EGFR,1956,AMPLIFICATION,NA,NA,https://civic.genome.wustl.edu/api/variants/190,190,7,55086794,55279321,NA,NA,GRCh37,Prognostic,B: Clinical evidence,The group of 43 out of 75 tumor samples with increased copy number or amplification of EGFR as determined by FISH (FISH-positive) had worse progression-free and overall survival than FISH-negative tumors.,Supports,Poor Outcome,Somatic Mutation,accepted,evidence,16943533,"<a href='http://www.ncbi.nlm.nih.gov/pubmed/16943533' target='_blank'>Chung et al., 2006, J. Clin. Oncol.</a>",Head And Neck Squamous Cell Carcinoma,5520,http://www.disease-ontology.org/?id=DOID:5520,NA,NA,4
EGFR,1956,AMPLIFICATION,NA,NA,https://civic.genome.wustl.edu/api/variants/190,190,7,55086794,55279321,NA,NA,GRCh37,Predictive,B: Clinical evidence,"In 290 patients with advanced NSCLC, 177 of which were treated with EGFR TKI (erlotinib or gefitinib). EGFR amplification (Multiplex ligation-dependent probe amplification; MLPA) and Mutation (PCR) were analzed. EGFR amplification was associated with EGFR mutation but not independently with patient benefit from EGFR TKI (overall and progression-free survival).",Does Not Support,Sensitivity,Somatic Mutation,accepted,evidence,26722081,"<a href='http://www.ncbi.nlm.nih.gov/pubmed/26722081' target='_blank'>Fiala et al., 2016, Anticancer Res.</a>",Non-small Cell Lung Carcinoma,3908,http://www.disease-ontology.org/?id=DOID:3908,"Erlotinib, Gefitinib",Substitutes,2
EGFR,1956,AMPLIFICATION,NA,NA,https://civic.genome.wustl.edu/api/variants/190,190,7,55086794,55279321,NA,NA,GRCh37,Prognostic,B: Clinical evidence,"In patients with Barrett's adenocarcinoma, those with amplification of EGFR had shorter disease-specific survial.",Supports,Poor Outcome,Somatic Mutation,accepted,evidence,20840671,"<a href='http://www.ncbi.nlm.nih.gov/pubmed/20840671' target='_blank'>Marx et al., 2010, Histopathology</a>",Barrett's Adenocarcinoma,7941,http://www.disease-ontology.org/?id=DOID:7941,NA,NA,3
EGFR,1956,AMPLIFICATION,NA,NA,https://civic.genome.wustl.edu/api/variants/190,190,7,55086794,55279321,NA,NA,GRCh37,Predictive,B: Clinical evidence,EGFR amplification was not a predictor of response to cetuximab/5-FU/platinum in patients with recurrent or metastatic HNSSC from the EXTREME study.,Does Not Support,Sensitivity,Somatic Mutation,accepted,evidence,21048039,"<a href='http://www.ncbi.nlm.nih.gov/pubmed/21048039' target='_blank'>Licitra et al., 2011, Ann. Oncol.</a>",Head And Neck Squamous Cell Carcinoma,5520,http://www.disease-ontology.org/?id=DOID:5520,"5-fluorouracil, Cetuximab, PLATINUM",Combination,4
EGFR,1956,AMPLIFICATION,NA,NA,https://civic.genome.wustl.edu/api/variants/190,190,7,55086794,55279321,NA,NA,GRCh37,Predictive,D: Preclinical evidence,"Evidence of wild-type allele-mediated resistance, a novel concept of acquired resistance in response to mutation-selective inhibitor therapy in cancer treatment. This study reports that the Src-AKT pathway contributes to acquired resistance to third generation EGFR TKIs. In addition, amplification of EGFR wild-type alleles but not mutant alleles was sufficient to confer acquired resistance.",Supports,Resistance or Non-Response,Somatic Mutation,accepted,evidence,28202511,"<a href='http://www.ncbi.nlm.nih.gov/pubmed/28202511' target='_blank'>Nukaga et al., 2017, Cancer Res.</a>",Non-small Cell Lung Carcinoma,3908,http://www.disease-ontology.org/?id=DOID:3908,"Rociletinib, Osimertinib",Substitutes,3
EGFR,1956,AMPLIFICATION,NA,NA,https://civic.genome.wustl.edu/api/variants/190,190,7,55086794,55279321,NA,NA,GRCh37,Predictive,B: Clinical evidence,"In this meta-analysis (14 studies, 1021 patients), EGFR gene copy number (GCN) was predictive of improved progression free survival (PFS) and overall survival (OS) with cetuximab or panitumumab regardless of KRAS status. For the pooled analysis, the objective response rate (ORR) was 65.2% (167/256) in patients with high EFGR GCN, while in patients with low EFGR GCN, the pooled ORR was 12.2% (44/361). The odds ratio (OR) was 6.905 (95% CI: 4.489-10.620; Z=8.79, P=0.000). In wild type KRAS patients, the pooled OR was 8.133 (95% CI: 4.316-15.326; Z=6.48, P=0.000).",Supports,Sensitivity,Somatic Mutation,accepted,evidence,24653627,"<a href='http://www.ncbi.nlm.nih.gov/pubmed/24653627' target='_blank'>Shen et al., 2014, Chin. J. Cancer Res.</a>",Colorectal Cancer,9256,http://www.disease-ontology.org/?id=DOID:9256,"Panitumumab, Cetuximab",Substitutes,3
EGFR,1956,AMPLIFICATION,NA,NA,https://civic.genome.wustl.edu/api/variants/190,190,7,55086794,55279321,NA,NA,GRCh37,Predictive,B: Clinical evidence,"A meta-analysis of EGFR gene copy number as a predictive biomarker for patients receiving tyrosine kinase inhibitor treatment was performed. In total, 20 (1689 patients, 594 with increased gene copy number), 10 (822 patients, 290 with increased gene copy number) and 5 studies (294 patients, 129 with increased gene copy number) were analyzed for overall survival (OS), progression-free survival (PFS) and time-to-progression (TTP) meta-analyses respectively. EGFR amplification was associated with increased OS (HR = 0.77; 95% CI 0.66-0.89; P = 0.001), PFS (HR = 0.60; 95% CI 0.46-0.79; P<0.001) and TTP (HR = 0.50; 95% CI 0.28-0.91; P = 0.02). This effect was shown to influence survival in predominantly white patient populations but not patients of Asian descent.",Supports,Sensitivity,Somatic Mutation,accepted,evidence,20826716,"<a href='http://www.ncbi.nlm.nih.gov/pubmed/20826716' target='_blank'>Dahabreh et al., 2011, Ann. Oncol.</a>",Non-small Cell Lung Carcinoma,3908,http://www.disease-ontology.org/?id=DOID:3908,EGFR Inhibitor,NA,4
EGFR,1956,AMPLIFICATION,NA,NA,https://civic.genome.wustl.edu/api/variants/190,190,7,55086794,55279321,NA,NA,GRCh37,Predictive,B: Clinical evidence,"87 patients with metastatic colorectal cancer treated with cetuximab were retrospectively analyzed for EGFR amplifications by FISH. In multivariate analysis, EGFR amplification predicted response and overall survival independent of KRAS status.",Supports,Sensitivity,Somatic Mutation,accepted,evidence,18794099,"<a href='http://www.ncbi.nlm.nih.gov/pubmed/18794099' target='_blank'>Personeni et al., 2008, Clin. Cancer Res.</a>",Colorectal Cancer,9256,http://www.disease-ontology.org/?id=DOID:9256,Cetuximab,NA,3
EGFR,1956,EXON 19 DELETION,"Deletions within exon 19 of EGFR are most common in lung cancer. These deletions, in non-small cell lung cancer, have been shown to be sensitive to the EGFR tyrosine kinase inhibitors gefitinib, afatinib, and erlotinib. There is also data to suggest that this event is a good prognostic marker in lung adenocarcinoma.",NA,https://civic.genome.wustl.edu/api/variants/133,133,7,55242415,55242513,NA,NA,GRCh37,Predictive,D: Preclinical evidence,Cells harboring an exon 19 deletion were sensitive to afatinib. This study performed drug response assays using five human NSCLC cell lines with various combinations of EGFR mutations. In order to directly compare the sensitivity of multiple EGFR mutations to EGFR-TKIs the authors also generated multiple EGFR transduced Ba/F3 stable cell lines and evaluated sensitivity to EGFR-TKIs by MTS assay.,Supports,Sensitivity,Somatic Mutation,accepted,evidence,26515464,"<a href='http://www.ncbi.nlm.nih.gov/pubmed/26515464' target='_blank'>Hirano et al., 2015, Oncotarget</a>",Non-small Cell Lung Carcinoma,3908,http://www.disease-ontology.org/?id=DOID:3908,Afatinib,NA,2
EGFR,1956,EXON 19 DELETION,"Deletions within exon 19 of EGFR are most common in lung cancer. These deletions, in non-small cell lung cancer, have been shown to be sensitive to the EGFR tyrosine kinase inhibitors gefitinib, afatinib, and erlotinib. There is also data to suggest that this event is a good prognostic marker in lung adenocarcinoma.",NA,https://civic.genome.wustl.edu/api/variants/133,133,7,55242415,55242513,NA,NA,GRCh37,Predictive,B: Clinical evidence,"In a phase 2 study (NCT00525148), patients with lung adenocarcinoma (stage IIIb with pleural effusion or stage IV) and EGFR mutations, treated with afatinib, were assessed by objective response. In total, 129 patients were treated with afatinib. 66% of the 106 patients with two common activating EGFR mutations (exon 19 deletion or L858R) had an objective response compared to 39% of 23 patients with less common EGFR mutations.",Supports,Sensitivity,Somatic Mutation,accepted,evidence,22452895,"<a href='http://www.ncbi.nlm.nih.gov/pubmed/22452895' target='_blank'>Yang et al., 2012, Lancet Oncol.</a>",Lung Adenocarcinoma,3910,http://www.disease-ontology.org/?id=DOID:3910,Afatinib,NA,3
EGFR,1956,EXON 19 DELETION,"Deletions within exon 19 of EGFR are most common in lung cancer. These deletions, in non-small cell lung cancer, have been shown to be sensitive to the EGFR tyrosine kinase inhibitors gefitinib, afatinib, and erlotinib. There is also data to suggest that this event is a good prognostic marker in lung adenocarcinoma.",NA,https://civic.genome.wustl.edu/api/variants/133,133,7,55242415,55242513,NA,NA,GRCh37,Predictive,B: Clinical evidence,NSCLC patients with exon 19 deletions in EGFR had longer overall survival than patients with an L858R mutation when treated with gefitinib or erlotinib (38 versus 17 months; P = 0.04).,Supports,Sensitivity,Somatic Mutation,accepted,evidence,16818686,"<a href='http://www.ncbi.nlm.nih.gov/pubmed/16818686' target='_blank'>Jackman et al., 2006, Clin. Cancer Res.</a>",Non-small Cell Lung Carcinoma,3908,http://www.disease-ontology.org/?id=DOID:3908,"Erlotinib, Gefitinib",Substitutes,4
EGFR,1956,EXON 19 DELETION,"Deletions within exon 19 of EGFR are most common in lung cancer. These deletions, in non-small cell lung cancer, have been shown to be sensitive to the EGFR tyrosine kinase inhibitors gefitinib, afatinib, and erlotinib. There is also data to suggest that this event is a good prognostic marker in lung adenocarcinoma.",NA,https://civic.genome.wustl.edu/api/variants/133,133,7,55242415,55242513,NA,NA,GRCh37,Predictive,C: Case study,"In a stage IV lung adenocarcinoma patient harboring EGFR exon 19 deletion, EGFR exon 19 deletion was associated with sensitivity to erlotinib monotherapy. Prior to identification of the EGFR exon 19 deletion, the patient was underwent complex treatments with standard chemotherapy and experienced disease progression; upon identification of EGFR exon 19 deletion and treatment with erlotinib, the patient achieved a clinical response.",Supports,Sensitivity,Somatic Mutation,accepted,evidence,27566387,"<a href='http://www.ncbi.nlm.nih.gov/pubmed/27566387' target='_blank'>Kanemaru et al., 2016, Respir Investig</a>",Lung Adenocarcinoma,3910,http://www.disease-ontology.org/?id=DOID:3910,Erlotinib,NA,NA
EGFR,1956,EXON 19 DELETION,"Deletions within exon 19 of EGFR are most common in lung cancer. These deletions, in non-small cell lung cancer, have been shown to be sensitive to the EGFR tyrosine kinase inhibitors gefitinib, afatinib, and erlotinib. There is also data to suggest that this event is a good prognostic marker in lung adenocarcinoma.",NA,https://civic.genome.wustl.edu/api/variants/133,133,7,55242415,55242513,NA,NA,GRCh37,Predictive,B: Clinical evidence,"A phase III clinical trial (NCT00949650) found that median progression free survival among patients with EGFR exon 19 deletion was 13.6 months for afatinib and 6.9 months for chemotherapy (HR, 0.47; 95% CI, 0.34 to 0.65; P = .001). 308 patients had either exon 19 or L858 mutations.",Supports,Sensitivity,Somatic Mutation,accepted,evidence,23816960,"<a href='http://www.ncbi.nlm.nih.gov/pubmed/23816960' target='_blank'>Sequist et al., 2013, J. Clin. Oncol.</a>",Lung Adenocarcinoma,3910,http://www.disease-ontology.org/?id=DOID:3910,Afatinib,NA,4
EGFR,1956,EXON 19 DELETION,"Deletions within exon 19 of EGFR are most common in lung cancer. These deletions, in non-small cell lung cancer, have been shown to be sensitive to the EGFR tyrosine kinase inhibitors gefitinib, afatinib, and erlotinib. There is also data to suggest that this event is a good prognostic marker in lung adenocarcinoma.",NA,https://civic.genome.wustl.edu/api/variants/133,133,7,55242415,55242513,NA,NA,GRCh37,Predictive,B: Clinical evidence,"In analysis of LUX-Lung 3 and LUX-Lung 6 trials (NCT00949650 and NCT01121393), of EGFR mutant NSCLC, median overall survival with afatinib treatment was seen to be significantly improved over chemotherapy (33.3 vs 21.1 and 31.4 vs 18.4 months in LUX-Lung 3 and LUX-Lung 6 respectively).  This effect was observed in the EGFR exon 19 deletion subgroup, but not in the L858R mutant subgroup.",Supports,Sensitivity,Somatic Mutation,accepted,evidence,25589191,"<a href='http://www.ncbi.nlm.nih.gov/pubmed/25589191' target='_blank'>Yang et al., 2015, Lancet Oncol.</a>",Lung Adenocarcinoma,3910,http://www.disease-ontology.org/?id=DOID:3910,Afatinib,NA,4
EGFR,1956,EXON 19 DELETION,"Deletions within exon 19 of EGFR are most common in lung cancer. These deletions, in non-small cell lung cancer, have been shown to be sensitive to the EGFR tyrosine kinase inhibitors gefitinib, afatinib, and erlotinib. There is also data to suggest that this event is a good prognostic marker in lung adenocarcinoma.",NA,https://civic.genome.wustl.edu/api/variants/133,133,7,55242415,55242513,NA,NA,GRCh37,Predictive,D: Preclinical evidence,Stable HEK293 cell lines expressing mutant EGFR cDNAs were created (using a pQCLIN retroviral vector) and their drug sensitivities to afatinib were examined by MTT assay. Phorphorylation of EGFR was assayed by Western blot. The 50% inhibitory concentration (IC50) of afatinib was significantly lower in cells harboring EGFR exon 19 deletion than in cells harboring EGFR L858R.,Supports,Sensitivity,Somatic Mutation,accepted,evidence,25862853,"<a href='http://www.ncbi.nlm.nih.gov/pubmed/25862853' target='_blank'>Banno et al., 2015, Anticancer Res.</a>",Non-small Cell Lung Carcinoma,3908,http://www.disease-ontology.org/?id=DOID:3908,Afatinib,NA,2
EGFR,1956,EXON 19 DELETION,"Deletions within exon 19 of EGFR are most common in lung cancer. These deletions, in non-small cell lung cancer, have been shown to be sensitive to the EGFR tyrosine kinase inhibitors gefitinib, afatinib, and erlotinib. There is also data to suggest that this event is a good prognostic marker in lung adenocarcinoma.",NA,https://civic.genome.wustl.edu/api/variants/133,133,7,55242415,55242513,NA,NA,GRCh37,Predictive,A: Validated,"On May 14, 2013, the U.S. Food and Drug Administration approved erlotinib (Tarceva) for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations.",Supports,Sensitivity,Somatic Mutation,accepted,evidence,24868098,"<a href='http://www.ncbi.nlm.nih.gov/pubmed/24868098' target='_blank'>Khozin et al., 2014, Oncologist</a>",Non-small Cell Lung Carcinoma,3908,http://www.disease-ontology.org/?id=DOID:3908,Erlotinib,NA,5
EGFR,1956,EXON 19 DELETION,"Deletions within exon 19 of EGFR are most common in lung cancer. These deletions, in non-small cell lung cancer, have been shown to be sensitive to the EGFR tyrosine kinase inhibitors gefitinib, afatinib, and erlotinib. There is also data to suggest that this event is a good prognostic marker in lung adenocarcinoma.",NA,https://civic.genome.wustl.edu/api/variants/133,133,7,55242415,55242513,NA,NA,GRCh37,Predictive,A: Validated,"Afatinib, an irreversible inhibitor of the ErbB family of tyrosine kinases has been approved in the US for the first-line treatment of patients with metastatic non-small-cell lung cancer (NSCLC) who have tumours with EGFR exon 19 deletions or exon 21 (L858R) substitution mutations as detected by a US FDA-approved test",Supports,Sensitivity,Somatic Mutation,accepted,evidence,23982599,"<a href='http://www.ncbi.nlm.nih.gov/pubmed/23982599' target='_blank'>Dungo et al., 2013, Drugs</a>",Non-small Cell Lung Carcinoma,3908,http://www.disease-ontology.org/?id=DOID:3908,Afatinib,NA,5
EGFR,1956,EXON 19 DELETION,"Deletions within exon 19 of EGFR are most common in lung cancer. These deletions, in non-small cell lung cancer, have been shown to be sensitive to the EGFR tyrosine kinase inhibitors gefitinib, afatinib, and erlotinib. There is also data to suggest that this event is a good prognostic marker in lung adenocarcinoma.",NA,https://civic.genome.wustl.edu/api/variants/133,133,7,55242415,55242513,NA,NA,GRCh37,Predictive,D: Preclinical evidence,Exon 19 deletion has been shown to be correlated with gefitinib response.,Supports,Sensitivity,Somatic Mutation,accepted,evidence,16730237,"<a href='http://www.ncbi.nlm.nih.gov/pubmed/16730237' target='_blank'>Ji et al., 2006, Cancer Cell</a>",Non-small Cell Lung Carcinoma,3908,http://www.disease-ontology.org/?id=DOID:3908,Gefitinib,NA,4
EGFR,1956,EXON 19 DELETION,"Deletions within exon 19 of EGFR are most common in lung cancer. These deletions, in non-small cell lung cancer, have been shown to be sensitive to the EGFR tyrosine kinase inhibitors gefitinib, afatinib, and erlotinib. There is also data to suggest that this event is a good prognostic marker in lung adenocarcinoma.",NA,https://civic.genome.wustl.edu/api/variants/133,133,7,55242415,55242513,NA,NA,GRCh37,Predictive,B: Clinical evidence,"90 NSCLC patients with stage IIIB/IV chemotherapy-resistant tumors were treated with gefitinib, and exon 19 deletion of EGFR was associated with longer time to treatment failure than those with wild-type EGFR (median 8.9 versus 2.1). In multivariate analysis, exon 19 deletion was a significant predictive factor for TTF (HR = 0.0320; P < .0001).",Supports,Sensitivity,Somatic Mutation,accepted,evidence,18509184,"<a href='http://www.ncbi.nlm.nih.gov/pubmed/18509184' target='_blank'>Yang et al., 2008, J. Clin. Oncol.</a>",Non-small Cell Lung Carcinoma,3908,http://www.disease-ontology.org/?id=DOID:3908,Gefitinib,NA,3
EGFR,1956,EXON 19 DELETION,"Deletions within exon 19 of EGFR are most common in lung cancer. These deletions, in non-small cell lung cancer, have been shown to be sensitive to the EGFR tyrosine kinase inhibitors gefitinib, afatinib, and erlotinib. There is also data to suggest that this event is a good prognostic marker in lung adenocarcinoma.",NA,https://civic.genome.wustl.edu/api/variants/133,133,7,55242415,55242513,NA,NA,GRCh37,Predictive,B: Clinical evidence,"In a phase 3 clinical trial of Korean, never-smoker, lung adenocarcinoma patients, a subset of patients with EGFR mutations (n=42) treated with gefitinib were associated with improved overall response rate compared to gemcitabine plus cisplatin treatment (84.6%, 22/26, vs. 37.5%, 6/16, P=0.002). By contrast, in EGFR mutation negative cases, the response rate was much lower (25.9%, 7/27). The frequency of mutation in exon 19 deletion and L858R was 64.3% (27/42) and 36.4% (16/42), respectively. Exon 19 and L858R mutations were mutually exclusive in this cohort.",Supports,Sensitivity,Somatic Mutation,accepted,evidence,22370314,"<a href='http://www.ncbi.nlm.nih.gov/pubmed/22370314' target='_blank'>Han et al., 2012, J. Clin. Oncol.</a>",Lung Adenocarcinoma,3910,http://www.disease-ontology.org/?id=DOID:3910,Gefitinib,NA,3
EGFR,1956,EXON 19 DELETION,"Deletions within exon 19 of EGFR are most common in lung cancer. These deletions, in non-small cell lung cancer, have been shown to be sensitive to the EGFR tyrosine kinase inhibitors gefitinib, afatinib, and erlotinib. There is also data to suggest that this event is a good prognostic marker in lung adenocarcinoma.",NA,https://civic.genome.wustl.edu/api/variants/133,133,7,55242415,55242513,NA,NA,GRCh37,Predictive,B: Clinical evidence,"Non-small cell cancer patients from two studies [The ARCHER 1009 (NCT01360554) and A7471028 (NCT00769067)] with exon 19 deletion and L858R EGFR (Exon 21) mutations were pooled to compare the efficacy of dacomitinib to erlotinib. 121 patients with any EGFR mutation were enrolled, 101 had activating mutations in exon 19 or 21. Median progression-free survival and median survival were better following dacomitinib treatment (14.6 and 26.6 months, N=53) than erlotinib (9.6 and 23.2, P = 0.146 and P = 0.265, N=48). In exon 19 mutated patients (N=32 and 36) PFS was better for dacomitinib treated patients (HR of 0.585 [95% CI 0.335鈥?.024], two-sided log-rank, P = 0.058) but did not reach significance.",Supports,Sensitivity,Somatic Mutation,accepted,evidence,26768165,"<a href='http://www.ncbi.nlm.nih.gov/pubmed/26768165' target='_blank'>Ramalingam et al., 2016, Ann. Oncol.</a>",Non-small Cell Lung Carcinoma,3908,http://www.disease-ontology.org/?id=DOID:3908,"Dacomitinib, Erlotinib",Substitutes,3
EGFR,1956,EXON 19 DELETION,"Deletions within exon 19 of EGFR are most common in lung cancer. These deletions, in non-small cell lung cancer, have been shown to be sensitive to the EGFR tyrosine kinase inhibitors gefitinib, afatinib, and erlotinib. There is also data to suggest that this event is a good prognostic marker in lung adenocarcinoma.",NA,https://civic.genome.wustl.edu/api/variants/133,133,7,55242415,55242513,NA,NA,GRCh37,Predictive,B: Clinical evidence,Afatinib is an irreversible covalent inhibitor of EGFR (second generation). This Phase III clinical trial (LUX-Lung 6; NCT01121393) was performed in Asian patients with EGFR mutant advanced NSCLC. 364 eligible patients with EGFR mutations were assigned to afatinib (n=242) or gemcitabine and cisplatin (n=122) treatment. The trial observed significantly longer median progression-free survival with afatinib vs. gemcitabine and cisplatin treatment (11.0 vs. 5.6 months). Afatinib/Chemotherapy group compositions: 51.2/50.8 % del 19; 38/37.7 % Leu858Arg; 10.8/11.5 % Uncommon.,Supports,Sensitivity,Somatic Mutation,accepted,evidence,24439929,"<a href='http://www.ncbi.nlm.nih.gov/pubmed/24439929' target='_blank'>Wu et al., 2014, Lancet Oncol.</a>",Lung Adenocarcinoma,3910,http://www.disease-ontology.org/?id=DOID:3910,Afatinib,NA,4
EGFR,1956,EXON 19 DELETION,"Deletions within exon 19 of EGFR are most common in lung cancer. These deletions, in non-small cell lung cancer, have been shown to be sensitive to the EGFR tyrosine kinase inhibitors gefitinib, afatinib, and erlotinib. There is also data to suggest that this event is a good prognostic marker in lung adenocarcinoma.",NA,https://civic.genome.wustl.edu/api/variants/133,133,7,55242415,55242513,NA,NA,GRCh37,Predictive,B: Clinical evidence,"A randomized phase 3 trial involving 173 NSCLC patients with EGFR mutations (exon 19 deletion or L858R mutation in exon 21) with no history of chemotherapy for metastatic disease. Patients were randomly allocated (1:1) to receive either erlotinib or standard chemotherapy. The primary endpoint was progression-free survival (PFS). Median PFS was 9.7 months in the erlotinib group, compared with 5.2 months in the standard chemotherapy group.",Supports,Sensitivity,Somatic Mutation,accepted,evidence,22285168,"<a href='http://www.ncbi.nlm.nih.gov/pubmed/22285168' target='_blank'>Rosell et al., 2012, Lancet Oncol.</a>",Non-small Cell Lung Carcinoma,3908,http://www.disease-ontology.org/?id=DOID:3908,Erlotinib,NA,3
MET,4233,AMPLIFICATION,NA,NA,https://civic.genome.wustl.edu/api/variants/270,270,7,116312459,116436396,NA,NA,GRCh37,Predictive,C: Case study,"In an evaluation of a patient with crizotinib-sensitive lung adenocarcinoma, an MET-Amplification was identified using CGP.  The patient attained a reduction in the target lesions by 38.7%, and the patient maintained response for at least 5 months post-treatment.",Supports,Sensitivity,Somatic Mutation,accepted,evidence,25922291,"<a href='http://www.ncbi.nlm.nih.gov/pubmed/25922291' target='_blank'>Le et al., 2015, Clin Lung Cancer</a>",Lung Adenocarcinoma,3910,http://www.disease-ontology.org/?id=DOID:3910,Crizotinib,NA,3
MET,4233,AMPLIFICATION,NA,NA,https://civic.genome.wustl.edu/api/variants/270,270,7,116312459,116436396,NA,NA,GRCh37,Predictive,C: Case study,"Case report of a patient with MET amplification without high-level MET/CEP7 ratio, MET exon 14 mutation or overexpression who achieved rapid response to crizotinib.",Supports,Sensitivity,Somatic Mutation,accepted,evidence,26724472,"<a href='http://www.ncbi.nlm.nih.gov/pubmed/26724472' target='_blank'>Zhang et al., 2016, J Thorac Oncol</a>",Lung Adenocarcinoma,3910,http://www.disease-ontology.org/?id=DOID:3910,Crizotinib,NA,2
MET,4233,AMPLIFICATION,NA,NA,https://civic.genome.wustl.edu/api/variants/270,270,7,116312459,116436396,NA,NA,GRCh37,Predictive,D: Preclinical evidence,"In this study a gefitinib-sensitive cell-line (HCC827), acquired gefitinib resistance (HCC827 GR) by a focal amplification of MET.  Resistance was conferred by the MET amplification driving ERBB3 (HER3)-dependent activation of PI3K.",Supports,Resistance or Non-Response,Somatic Mutation,accepted,evidence,17463250,"<a href='http://www.ncbi.nlm.nih.gov/pubmed/17463250' target='_blank'>Engelman et al., 2007, Science</a>",Non-small Cell Lung Carcinoma,3908,http://www.disease-ontology.org/?id=DOID:3908,Gefitinib,NA,4
MET,4233,AMPLIFICATION,NA,NA,https://civic.genome.wustl.edu/api/variants/270,270,7,116312459,116436396,NA,NA,GRCh37,Predictive,C: Case study,"A case-study describing a patient with MET polysomy, MET over-expression and evidence of autocrine HGF-production (the growth factor ligand of MET). The patient initially achieved a complete response on MET-Inhibitor MetMAb (Onartuzumab) for 2 years and mixed response after recurrence with resistance in some of the newly developing metastases.",Supports,Sensitivity,Somatic Mutation,accepted,evidence,22389872,"<a href='http://www.ncbi.nlm.nih.gov/pubmed/22389872' target='_blank'>Catenacci et al., 2011, Cancer Discov</a>",Gastric Adenocarcinoma,3717,http://www.disease-ontology.org/?id=DOID:3717,Onartuzumab,NA,3
MET,4233,AMPLIFICATION,NA,NA,https://civic.genome.wustl.edu/api/variants/270,270,7,116312459,116436396,NA,NA,GRCh37,Predictive,D: Preclinical evidence,"Functional studies show that MET activation confers resistance to anti-EGFR therapy both in vitro and in vivo. Notably, in patient-derived colorectal cancer xenografts, MET amplification correlated with resistance to EGFR blockade, which could be overcome by MET kinase inhibitors.",Supports,Resistance or Non-Response,Somatic Mutation,accepted,evidence,23729478,"<a href='http://www.ncbi.nlm.nih.gov/pubmed/23729478' target='_blank'>Bardelli et al., 2013, Cancer Discov</a>",Colorectal Cancer,9256,http://www.disease-ontology.org/?id=DOID:9256,Anti-EGFR Monoclonal Antibody,NA,3
MET,4233,AMPLIFICATION,NA,NA,https://civic.genome.wustl.edu/api/variants/270,270,7,116312459,116436396,NA,NA,GRCh37,Predictive,C: Case study,"Case report of a patient with BRAF V600E mutant metastatic colorectal cancer. Combined EGFR and BRAF inhibition (panitumumab and vemurafenib) showed an initial partial response for 4 months. Re-biopsy at the time of progression showed a MET amplification and overexpression (IHC, ISH) but no secondary mutations in candidate resistance genes (EGFR, KRAS, NRAS, MAP2K1). MET amplification was also present in a subset of tumor cells in the pretreatment sample. MET amplification was also identified in 3/17 (18%) chemonaive BRAF V600E colorectal cancer tumor tissues.Overexpression of MET in a BRAF mutant CRC cell line (WiDr) confered resistance to combined vemurafenib and panitumumab. The addition of crizotinib to this combination restored sensitivity in vitro.The patient was started on combined vemurafenib and crizotinib in January 2016 and had a metabolic, clinical and tumor marker response that was ongoing at the time of publication (06/16) without significant toxicity.",Supports,Sensitivity,NA,accepted,evidence,27325282,"<a href='http://www.ncbi.nlm.nih.gov/pubmed/27325282' target='_blank'>Pietrantonio et al., 2016, Cancer Discov</a>",Colorectal Cancer,9256,http://www.disease-ontology.org/?id=DOID:9256,"Crizotinib, Vemurafenib",Combination,4
MET,4233,AMPLIFICATION,NA,NA,https://civic.genome.wustl.edu/api/variants/270,270,7,116312459,116436396,NA,NA,GRCh37,Predictive,D: Preclinical evidence,"Functional studies show that MET activation confers resistance to anti-EGFR therapy both in vitro and in vivo. Notably, in patient-derived colorectal cancer xenografts, MET amplification correlated with resistance to EGFR blockade, which could be overcome by MET kinase inhibitors.",Supports,Sensitivity,Somatic Mutation,accepted,evidence,23729478,"<a href='http://www.ncbi.nlm.nih.gov/pubmed/23729478' target='_blank'>Bardelli et al., 2013, Cancer Discov</a>",Colorectal Cancer,9256,http://www.disease-ontology.org/?id=DOID:9256,"Cetuximab, Crizotinib",Combination,3
MET,4233,AMPLIFICATION,NA,NA,https://civic.genome.wustl.edu/api/variants/270,270,7,116312459,116436396,NA,NA,GRCh37,Predictive,C: Case study,"155 patients with lung adenocarcinomas underwent rebiopsy and genotyping (EGFR, AKT1, BRAF, ERBB2, KRAS, MEK1, NRAS, PIK3CA and FISH for MET and HER2) after the development of acquired resistance to EGFR inhibitors (gefitinib or erlotinib). MET amplification was seen in 4 of 75 patients tested (no baseline samples available). One patient had small cell transformation and MET amplification, two patients had EGFR T790M mutation and MET amplification.",Supports,Resistance or Non-Response,NA,accepted,evidence,23470965,"<a href='http://www.ncbi.nlm.nih.gov/pubmed/23470965' target='_blank'>Yu et al., 2013, Clin. Cancer Res.</a>",Lung Adenocarcinoma,3910,http://www.disease-ontology.org/?id=DOID:3910,"Erlotinib, Gefitinib",Substitutes,2
MET,4233,AMPLIFICATION,NA,NA,https://civic.genome.wustl.edu/api/variants/270,270,7,116312459,116436396,NA,NA,GRCh37,Predictive,C: Case study,A case-study of an ALK-negative patient with MET amplification (MET/CEP7 ratio >5.0) who achieved a durable partial response to MET/ALK-inhibitor crizotinib.,Supports,Sensitivity,Somatic Mutation,accepted,evidence,21623265,"<a href='http://www.ncbi.nlm.nih.gov/pubmed/21623265' target='_blank'>Ou et al., 2011, J Thorac Oncol</a>",Non-small Cell Lung Carcinoma,3908,http://www.disease-ontology.org/?id=DOID:3908,Crizotinib,NA,3
MET,4233,AMPLIFICATION,NA,NA,https://civic.genome.wustl.edu/api/variants/270,270,7,116312459,116436396,NA,NA,GRCh37,Predictive,C: Case study,"A 62 year old female was diagnosed with glioblastoma (GBM) WHO grade 4. Treatment included radiation, temozolomide and cediranib. MET amplification was found by FISH, and ALK and MET inhibitor crizotinib treatment was started. A 40% reduction in size of contrast enhancing lesion was seen. After 6 months, progressive disease was seen and crizotinib withdrawn. The authors state this is a first report of response to prospective MET targeted therapy in GBM.",Supports,Sensitivity,Somatic Mutation,accepted,evidence,22162573,"<a href='http://www.ncbi.nlm.nih.gov/pubmed/22162573' target='_blank'>Chi et al., 2012, J. Clin. Oncol.</a>",Glioblastoma Multiforme,3068,http://www.disease-ontology.org/?id=DOID:3068,Crizotinib,NA,3
MET,4233,AMPLIFICATION,NA,NA,https://civic.genome.wustl.edu/api/variants/270,270,7,116312459,116436396,NA,NA,GRCh37,Predictive,C: Case study,"Case report of a 59-year-old white female patient (60 pack-years) with a CUP-syndrome. Molecular profiling identified both MET amplification (16 copies) and a KRAS G12V mutation. The patient was treated with crizotinib and experienced a complete normalization of tumor metabolic activity for more than 19 months. Other identified aberrations include CCND1 amplification (8 copies), MYC amplification (9 copies) as well as KRAS G12V, TP53 R273L and CARD11 N184S.",Supports,Sensitivity,NA,accepted,evidence,25232318,"<a href='http://www.ncbi.nlm.nih.gov/pubmed/25232318' target='_blank'>Palma et al., 2014, Case Rep Oncol</a>",Cancer,162,http://www.disease-ontology.org/?id=DOID:162,Crizotinib,NA,3
MET,4233,AMPLIFICATION,NA,NA,https://civic.genome.wustl.edu/api/variants/270,270,7,116312459,116436396,NA,NA,GRCh37,Predictive,D: Preclinical evidence,"2 MET amplified NSCLC cell lines (EBC-1 and H1993), as well as 2 EGFR mutant and 2 MET and EGFR wild type cell lines were treated with ALK and MET inhibitor crizotinib, and the MET amplified cells had IC50 100 fold lower than the non MET amplified cell lines. Both crizotinib treatment and siRNA against MET increased apoptotic markers in MET amplified cells but not controls, indicating that crizotinib targeting of amplified MET was inducing the apoptotic effects. Tumors caused by MET amplified EBC-1 cells injected into mice were significantly inhibited with crizotinib treatment, while tumors from non-MET amplified cells showed no substantial effect.",Supports,Sensitivity,Somatic Mutation,accepted,evidence,21716144,"<a href='http://www.ncbi.nlm.nih.gov/pubmed/21716144' target='_blank'>Tanizaki et al., 2011, J Thorac Oncol</a>",Non-small Cell Lung Carcinoma,3908,http://www.disease-ontology.org/?id=DOID:3908,Crizotinib,NA,4
MET,4233,AMPLIFICATION,NA,NA,https://civic.genome.wustl.edu/api/variants/270,270,7,116312459,116436396,NA,NA,GRCh37,Predictive,C: Case study,"Case report of a 73 year old patient with advanced squamous cell carcinoma of the lung that tested negative for EGFR, KRAS and PIK3CA mutations and ALK and ROS1 rearrangements. c-MET amplification was detected by FISH. Crizotinib led to a partial response.",Supports,Sensitivity,Somatic Mutation,accepted,evidence,24192513,"<a href='http://www.ncbi.nlm.nih.gov/pubmed/24192513' target='_blank'>Schwab et al., 2014, Lung Cancer</a>",Lung Squamous Cell Carcinoma,3907,http://www.disease-ontology.org/?id=DOID:3907,Crizotinib,NA,2
MET,4233,AMPLIFICATION,NA,NA,https://civic.genome.wustl.edu/api/variants/270,270,7,116312459,116436396,NA,NA,GRCh37,Predictive,C: Case study,Case report of two patients with MET amplification (MET:CEP7 ratio 鈮?) and no concomitant MET exon 14 deletion. A response to crizotinib was observed in both cases suggesting that MET amplification may predict response to this drug even in the absence of MET exon 14 mutations.,Supports,Sensitivity,NA,accepted,evidence,27664533,"<a href='http://www.ncbi.nlm.nih.gov/pubmed/27664533' target='_blank'>Caparica et al., 2017, J Thorac Oncol</a>",Non-small Cell Lung Carcinoma,3908,http://www.disease-ontology.org/?id=DOID:3908,Crizotinib,NA,2
SMAD4,4089,LOSS,NA,NA,https://civic.genome.wustl.edu/api/variants/564,564,18,48556583,48611409,NA,NA,GRCh37,Prognostic,B: Clinical evidence,"Study employed a rapid autopsy technique on a cohort of 76 patients with pancreatic cancer and explored the status of several genes. 63% (41/65) of carcinomas analyzed showed inactivation of SMAD4 (DPC4) via immunolabeling. Among the patterns of failure ""metastatic and locally destructive"", It was discovered that DPC4 loss was significantly associated with metastatic disease (p=.007).",Supports,Poor Outcome,Somatic Mutation,accepted,evidence,19273710,"<a href='http://www.ncbi.nlm.nih.gov/pubmed/19273710' target='_blank'>Iacobuzio-Donahue et al., 2009, J. Clin. Oncol.</a>",Pancreatic Cancer,1793,http://www.disease-ontology.org/?id=DOID:1793,NA,NA,3
CDKN2B,1030,LOSS,NA,NA,https://civic.genome.wustl.edu/api/variants/555,555,9,22002902,22009362,NA,NA,GRCh37,Predictive,D: Preclinical evidence,"A patient-derived xenograft (PDX) from a patient with cyclin-dependent kinase inhibitor 2A/B (CDKN2A/B) loss and FUS-ERG fusion positive Ewing's sarcoma was created. The PDX was treated in four cohorts (each N=6) with control, doxorubicin, CDK4/6 inhibitor palbociclib or IGF-1R inhibitor linsitinib. Both linsitinib and palbociclib cohorts were significantly more effective than control and doxorubicin. Doxorubicin was part of the patient's treatment (Neoadjuvant chemotherapy with DOX, vincristine, and cyclophosphamide) and was noted by authors as failing to control tumor growth.",Supports,Sensitivity,Somatic Mutation,accepted,evidence,27286459,"<a href='http://www.ncbi.nlm.nih.gov/pubmed/27286459' target='_blank'>Murakami et al., 2016, Oncotarget</a>",Ewing Sarcoma,3369,http://www.disease-ontology.org/?id=DOID:3369,"Linsitinib, Palbociclib",Substitutes,2
CDKN2B,1030,LOSS,NA,NA,https://civic.genome.wustl.edu/api/variants/555,555,9,22002902,22009362,NA,NA,GRCh37,Predictive,D: Preclinical evidence,"Preclinical study of CDK4/6 inhibitor PD-0332991 in 28 renal carcinoma cell lines (25 malignant RCC and three non-malignant, transformed cell lines derived from kidney epithelium). Both p15 and p16 loss (CGH) were tested for association with response to PD-0332991 using Fisher's exact test. Cell lines with p16 and p15 losses were significantly more likely to be classified as responders (defined by pharmacokinetic data-based concentration of <=400nM) to PD-0332991 (p=0.027, relative risk (RR)=2.06 and p=0.047, RR=1.71, respectively). Four cell lines had homozygous deletions of CDKN2A but not CDKN2B, and three of these lines were classified as being sensitive to PD-0332991. There were no cell lines with only CDKN2B deletion.",Supports,Sensitivity,Somatic Mutation,accepted,evidence,23898052,"<a href='http://www.ncbi.nlm.nih.gov/pubmed/23898052' target='_blank'>Logan et al., 2013, Anticancer Res.</a>",Renal Cell Carcinoma,4450,http://www.disease-ontology.org/?id=DOID:4450,Palbociclib (PD0332991),NA,3
